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(SEQ ID N0:07}
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(SEQ ID NO:OB}
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SEQIDN0:01: 1 pgsgqiqlwq fllellsdsa nascitwegt ngefkmtdpd evarrwgerk
skpnmnydkl sralryy~dk nimt~vhgkr l!Ykfdfhgi aqalqphp 98
SEQ ID NO: 02 1 pgsgqiqlwq
sralryy~dk

fllel:sdss nsscitwegt ngefkntdpd evarrwgerk skpnrrnydkl
nimt~vhgkr l!Ykfdfhgi aqalqphp 98
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SEMI-SYNTHETIC MITHRAMYCIN
DERIVATIVES WITH ANTI-CANCER
ACTIVITY

Although ETS transcription factors such as FLil and
ERG have been identified as critical targets in diseases such
as Ewing sarcoma, no therapies have yet moved from bench
to bedside that could impact the outcome of this disease.
Ewing sarcoma, which affects primarily children and young
adults is a difficult cancer to treat. Current therapy with a
combination of severely cytotoxic drugs provides up to 60%
long-term survival, but the cancer often recurs.
Recently, mithramycin (MTM), an aureolic acid natural
product previously used clinically against other cancers, was
identified as a potent (low-nM) inhibitor of EWS-FLil in
Ewing sarcoma cells (Grohar et a!., (2011) Journal of the
National Cancer Institute 103, 962-78). MTM exhibited
similar high potency against Ewing sarcoma tumor cells in
vitro and was efficacious in Ewing sarcoma mouse xenografts. Based on this study, MTM entered clinical trials at the
National Cancer Institute as a Ewing sarcoma therapeutic
(Clinica!Trials.gov, ID#NCT01610570) in 2012. Despite its
strong inhibitory properties towards Ewing sarcoma, MTM
was found to be highly toxic to non-Ewing cells, apparently
because it inhibits Sp transcription factors. Therefore, MTM
analogues that are more selective against Ewing sarcoma
cells and/or other cancers are needed.
It is clear that MTM has high potential in the fight against
cancer and new and improved analogues would find clinical
relevance. A need thus exists to improve the performance,
selectivity and efficacy of MTM.

CROSS-REFERENCE TO RELATED
APPLICATIONS
This application is a continuation application of PCT/
US2013/074725, filed Dec. 12, 2013, which claims the
benefit of U.S. Provisional Application No. 61/737,353 filed
Dec. 14, 2012, and this application claims the benefit of U.S.
Provisional Application No. 62/001,516, filed May 21,2014.
The entire disclosures of the foregoing PCT and Provisional
Patent Applications are hereby incorporated by reference
herein.
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10

15

SEQUENCE LISTING
The instant application contains a Sequence Listing which
has been submitted electronically in ASCII format and is
hereby incorporated by reference in its entirety. Said ASCII
copy, created on Jul. 23, 2015, is named 0502290635_SL.txt and is 12,125 bytes in size.
TECHNICAL FIELD
The present disclosure relates to mithramycin side chain
carboxylic acid (MTM SA) derivatives and their use in the
treatment of cancers. The present disclosure also relates to
methods for identifying MTM SA derivative compounds
that selectively modulate the activity of a target ETS transcription factor.

20

25

30

BACKGROUND
35

All members of the erythroblast transformation-specific
(ETS) transcription factor-family contain an Ets-domain
which consists of approximately 80 amino acids with four
tryptophan repeats. The Ets-domain binds to doublestranded DNA of target genes containing a GGAA/T core
motif and different flanking regions. Exemplary ETS transcription factors include Friend leukemia integration 1 transcription factor (FLil) and v-ets avian erythroblastosis virus
E26 oncogene-like transcription factor (ERG).
FLI1 aberrant regulation is often associated with malignant transformation and is associated with chromosomal
abnormalities in humans. For example, in Ewing Sarcoma
and primitive neuroectodermal tumors, a chromosomal
translocation results in a chimeric EWS-FLI 1 fusion protein,
containing the 5' region ofEWS (Ewing sarcoma breakpoint
region 1) and the 3' ETS region of Fli-1 (Delattre et a!.,
Nature. 1992 Sep. 10; 359(6391):162-5). This oncoprotein
acts as an aberrant transcriptional activator with strong
transforming capabilities. FLil and homologous transcription factors also have been implicated in human leukemias,
such as Acute Myelogenous Leukemia (AML), involving
loss or fusion of the tel gene, as well as other malignancies
including clear-cell sarcoma, myxoid liposarcoma, desmoplastic small round cell tumor, myxoid chondrosarcoma,
acute myeloid leukemia, congenital fibrosarcoma, prostate
cancer and pancreatic cancer.
Another ETS transcription factor, ERG, is implicated in
several cancers. Aberrant ERG regulation has been shown to
be associated with diseases including Ewing sarcoma, acute
myeloid leukemia (AML), prostate cancer, acute lymphoblatic leukemia (ALL), Alzheimer's disease (AD), and Down
syndrome (DS).

SUMMARY OF THE DISCLOSURE
In one aspect of the disclosure, certain MTM SA derivatives or their pharmaceutically acceptable salts are provided.
Such derivatives can be used in the treatment of various
cancers including Ewing sarcoma and various neuro-diseases. In certain embodiments there are provided MTM SA
derivatives having the following formula:

40

45

50

55

60

65

or a pharmaceutically acceptable salt thereof; wherein Z
represents 0, S, N-R'; R and R' represent, for each occurrence, H, alkyl, heterocyclic, aryl, heteroaryl, provided that
R is not H when Z is 0; ZR taken together represents an
organic residue, e.g., an amino acid conjugate or its ester
derivative; and wherein MTM 1 represents the fused ring
portion of the mithramycin structure and can include different sugars or sugar chains.
In certain embodiments, the MTM SA derivative is an
amide derivative, e.g. ZR together form a NR 1 R 2 group
where R 1 and R 2 can be the same or different and each of R 1
and R 2 can be an H, an amino acid conjugate or an ester
derivative thereof, a lower straight chain or branched alkyl.
In other embodiments, the MTM SA derivative is an amino
acid derivative, e.g. NR 1 R 2 together form an amino acid
conjugate or an ester derivative thereof. In certain embodiments, NR 1 R 2 is the amino acid conjugate phenylalanine
(e.g., MTM SA-Phe) or an ester derivative thereof. In other
embodiments, NR 1 R 2 is the amino acid conjugate tryptopharr (e.g., MTM SA-Trp) or its ester derivative. The amino
acid conjugate or its ester derivative thereof can further be
substituted. Substituents include, for example, -R3 Y where
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R 3 is alkyl, e.g., C 1 _16 or C 1 _8 alkyl, andY is a formyl ene,
expoxy, aryl, e.g., phenyl, heteroaryl, e.g., indolyl. In some
embodiments -R3 Y together form an ally lox group. In
another related embodiment, the MTM SA derivative
includes one or more sugar groups such as D-digitoxose. In
another related embodiment, the MTM SA derivative is
MTM SA-Phe or MTM SA-Trp that also includes one or
more different sugar moieties.
In another aspect, the subject technology provides a
method for screening MTM SA derivatives to identify
derivatives that selectively complex with and specifically
modulate the activity of a target ETS transcription factor that
has a DNA binding domain with an amino acid sequence that
is at least 85% identical to SEQ ID NO:Ol or SEQ ID N0:02
over the entire length of either of these sequences. In a
related embodiment, the screening method includes use of
an isolated mutant ETS transcription factor described herein.
In another related embodiment, the screening method
includes the step of (a) contacting a mithramycin derivative
as a test agent or a test agent other than mithramycin with a
target ETS transcription factor in the presence of an oligonucleotide substrate under conditions suitable for transcription of the oligonucleotide substrate; (b) detecting the specificity of the test agent for binding to and/or modulating the
activity of the target ETS transcription factor, and (c)
selecting test agents that exhibit specifically for and modulate the activity of the target ETS transcription factor relative
to a reference or control sample or one or more other ETS
transcription factors. In another embodiment, the screening
method includes the steps of (a) contacting a mithramycin
derivative as a test agent or a test agent other than mithramycin with the target ETS transcription factor in the
presence of an oligonucleotide substrate; (b) assessing the
effect of the test agent on the activity of the target ETS
transcription factor; and (c) selecting test agents that exhibit
specificity for and modulate the activity of the ETS transcription factor relative to a reference or control sample or
one or more other ETS transcription factors.
In another embodiment relating to this aspect, the target
ETS transcription factor is Friend leukemia integration 1
transcription factor (FLil) or v-ets avian erythroblastosis
virus E26 oncogene-like transcription factor (ERG). In
another related embodiment relating to this aspect, the
specificity of the test agent for the target ETS transcription
is assessed by detecting the formation and/or stability of a
complex formed between the transcription factor and its
oligonucleotide substrate in the presence of the test agent
relative to a reference or control sample or one or more other
ETS transcription factors. In another related embodiment,
the effect of the test agent on the activity the transcription
factor is assessed by detecting the formation and/or stability
of a complex formed between the transcription factor and
the oligonucleotide substrate in the presence of the test agent
relative to a reference or control sample. In another related
embodiment, the activity of the test agent is assessed by
measuring the effect of the test compound on the affinity of
the transcription factor for the oligonucleotide substrate. In
another related embodiment, step (b) discussed above further includes assessing the formation of a complex comprising the MTM SA derivative, the target ETS transcription
factor and the oligonucleotide substrate.
In another aspect, the subject technology provides a
method for modulating the activity of a target erythroblast
transformation-specific (ETS) transcription factor in a
patient in need thereof, including administering to the
patient a therapeutically effective amount of an MTM SA

derivative or a pharmaceutically acceptable salt thereof
having the following formula:
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or a pharmaceutically acceptable salt thereof; wherein Z and
R represent the same groups as described herein, including
all of the various embodiments thereof.
In another aspect, the subject technology provides a
method of treating a target ETS transcription factor-mediated disease in a patient by administering to the patient a
therapeutically effective amount of an MTM SA-Phe, MTM
SA-Trp or any other MTM SA derivative described herein,
wherein the MTM SA derivative specifically modulates the
activity of the ETS transcription factor mediating the disease
and wherein the target ETS-mediated disease is Ewing
sarcoma, clear-cell sarcoma, myxoid liposarcoma, desmoplastic small round cell tumor, myxoid chondrosarcoma,
acute myeloid leukemia, congenital fibrosarcoma, prostate
cancer or pancreatic cancer. In an embodiment of this aspect,
the target ETS transcription factor specifically modulated is
Friend leukemia integration 1 transcription factor (FLil) or
v-ets avian erythroblastosis virus E26 oncogene-like transcription factor (ERG).
In another aspect, the subject technology provides an
isolated non-naturally-occurring mutant or engineered ETS
transcription factor that comprises a DNA binding domain
having the sequences of SEQ ID N0:01 or SEQ ID N0:02,
wherein the transcription factor includes at least one amino
acid substitution at any of amino acid residues corresponding to residues Tyr68, Lys75, His77, Gly78, Lys79, Arg80,
Tyr81, Ala82 of SEQ ID NO:Ol or SEQ ID N0:02. In an
embodiment relating to this aspect, the engineered ETS
transcription factor comprises a DNA binding domain that is
at least 85% identical to SEQ ID NO:Ol or SEQ ID N0:02
over the entire length of either of these sequences. In another
related embodiment the engineered ETS transcription factor
is Friend leukemia integration 1 transcription factor (FLil)
or v-ets avian erythroblastosis virus E26 oncogene-like
transcription factor (ERG). In another related embodiment,
the engineered ETS transcription factor has a substantially
similar, increased, or decreased DNA binding activity relative to the DNA binding activity of a wild-type ETS transcription factor.
Additional advantages of the present invention will
become readily apparent to those skilled in this art from the
following detailed description, wherein only the preferred
embodiment of the invention is shown and described, simply
by way of illustration of the best mode contemplated of
carrying out the invention. As will be realized, the invention
is capable of other and different embodiments, and its
several details are capable of modifications in various obvious respects, all without departing from the invention.
Accordingly, the drawings and description are to be regarded
as illustrative in nature, and not as restrictive.
BRIEF DESCRIPTION OF THE DRAWINGS
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Reference is made to the attached drawings, wherein
elements having the same reference numeral designations
represent similar elements throughout and wherein:
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FIG. 1 is a schematic representation of the accumulation
ofMTM SK, MTM SDK, and MTM SA by the inactivation
of the mtm W gene in the MTM biosynthetic pathway.
FIG. 2 illustrates two ways to produce the starting material MTM SA and also shows various MTM SA derivatives.
FIG. 3 illustrated functionalization of MTM SA through
a reaction with a primary amine containing compound.
Representative compounds are shown.
FIG. 4 illustrates five exemplary MTM SA derivatives
that exhibit high specificity for EWS-FLI1 transcription
factor in Ewing sarcoma.
FIG. 5 illustrates certain MTM SA derivatives including
substituted MTM SA-Trp and MTM SA-Phe.
FIG. 6 shows the amino acid sequence (SEQ ID NO: 7)
of FLI1 transcription factor, with the DNA binding domain
in that sequence highlighted.
FIG. 7 shows the amino acid sequence (SEQ ID NO: 8)
of ERG transcription factor, with the DNA binding domain
in that sequence highlighted.
FIG. 8 shows a comparison between the amino acid
sequences of the DNA binding domains of FLil (SEQ ID
NO:Ol) and ERG (SEQ ID N0:02), with the MTM interacting residues underlined.
FIG. 9 illustrates the average absolute (left) and relative
(right) cytotoxicity (to cell proliferation) of MTM and its
analogues against Ewing sarcoma (EWS) relative to nonEwing sarcoma cell lines.
FIG. 10 shows the potency and specificity of MTM
SA-Phe in killing of Ewing sarcoma cells.
FIG. llA, FIG. llB, FIGS. llC, llD, and llE provide a
series of graphs showing that MTM analogs have increased
cytoxicity and distinct cell cycle distribution in Ewing
sarcoma. The graphs show relative gene expression in TC32
cells treated with MTM analogs. Three genes controlled by
the EWS-FLil transcription factor were investigated by
qRT-PCR at four different treatment concentrations for 6
hours. CCK served as a negative control.
FIG. 12(a) shows the 72-hour cytotoxicity results in
TC32, 5838, SK-ES-1, RD-ES, TC71, RH-30, A673, ES-2,
ES-3, ES-4, ES-7, ES-8 Ewing sarcoma cell lines (o EWS)
and A549, PC3, DU145, OVCAR-8, C42, VCap, LNCap,
U118 non-Ewing sarcoma cell lines (DNon-EWS). FIG.
12(b) is a FACs analysis ofTC32 cells treated with 100 nM
of drug for 24 hours.

function of EWS-FLI1 required for oncogenesis and tumor
progression. The inventors have identified certain MTM SA
derivatives including MTM SA-Phe and MTM SA-Trp that
exhibit greater selectivity for EWS-FLil transcription factor
and against Ewing's sarcoma cells than MTM itself.
The systematic investigations of the DNA interaction of
certain of these lead drugs led to discovery of the mechanism
of action of MTM, which not only explains all effects of
MTM observed thus far, but now serves as the basis for
further systematic improvement and fine-tuning of the lead
analogues. Briefly, the inventors have found that MTM
increases the binding affinity of EWS-FLI1 to promoter
DNA both by DNA remodeling and through specific direct
MTM-EWS-FLil interactions, i.e., locks a ternary drugDNA-transcription factor complex. This mechanism is fundamentally different from the generally accepted mechanism
of action of MTM (displacement of Sp-type transcription
factors from the DNA promoter region by MTM), which can
account for the general toxicity of MTM, but caunot explain
its potent and selective antagonism of EWS-FLil. The
discovery of a direct interaction between MTM, bound in the
minor groove of the DNA, and the transcription factor
EWS-FLI1, bound in the nearby major groove, was utilized
to generate optimized MTM analogues with increased specificity for a target transcription factor.
In the following detailed description, numerous specific
details are set forth to provide a full understanding of the
subject technology. It will be apparent, however, to one of
ordinarily skilled in the art that the subject technology may
be practiced without some of these specific details. In other
instances, well-known structures and techniques have not
been shown in detail so as not to obscure the subject
technology.
All references cited herein are incorporated by reference
in their entirety as though fully set forth. Unless defined
otherwise, technical and scientific terms used herein have
the same meaning as commonly understood by one of
ordinary skill in the art to which subject technology belongs.
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DETAILED DESCRIPTION OF THE
DISCLOSURE
The MTM SA derivatives disclosed herein are examples
of modified natural products that exhibit improved anticanceractivity in comparision to the natural product. It is
believed that MTM acts by cross-linking GC-rich DNA
thereby shutting down the transcription of several protooncogenes, particularly pathways regulated by transcription
factors Sp1 and Sp3. The Sp1 transcription factors are
important as they have been linked to the control of cell
growth, survival, and differentiation and their overexpression has been observed in several cancers.
Extensive combinatorial biosynthesis has been performed
on the drug biosynthesis pathway to produce altered MTM
analogues for the purpose of improving their toxicity profiles. This has resulted in several novel useful compounds
for the treatment of Ewing sarcoma and other cancers.
The inventors have discovered inter alia that MTM SA
binds DNA substrate together and cooperatively with EWSFLil, resulting in a ternary MTM SA: DNA substrate:EWSFLil complex, which, in turn, perturbs the transcription
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DEFINITIONS
To facilitate an understanding of the present subject
technology, a number of terms and phrases are defined
below:
A reference to an element in the singular is not intended
to mean "one and only one" unless specifically stated, but
rather "one or more."
As used herein, a "target ETS transcription factor" refers
to a transcription factor which comprises a DNA-binding
domain (DBD) having an amino acid sequence that is at least
85% identical to SEQ ID N0:01 or SEQ ID N0:02 over the
entire length of either of these sequences. SEQ ID NO:Ol
and SEQ ID N0:02 are provided in FIG. 8.
As used herein the term "modulator," "modulating," or
"modulate" in connection with the target ETS transcription
factor of the subject technology refers to any agent that has
a functional effect on the transcription factor, including
positively or negatively affecting its binding to a DNA
substrate, positively or negatively affecting the formation
and/or stability of a complex formed between the transcription factor and its oligonucleotide substrate, positively or
negatively affecting its function in causing the transcription
of its oligonucleotide substrate.
As used herein, the term "vector" is a composition of
matter which comprises an isolated nucleic acid and which
can be used to deliver the isolated nucleic acid to the interior
of a cell. Numerous vectors are known in the art including,
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but not limited to, linear polynucleotides, polynucleotides
associated with ionic or amphiphilic compounds, plasmids,
and viruses. Thus, the term "vector" includes an autonomously replicating plasmid or a virus. The term should also
be construed to include non-plasmid and non-viral compounds which facilitate transfer of nucleic acid into cells,
such as, for example, poly lysine compounds, liposomes, and
the like. Examples of viral vectors include, but are not
limited to, adenoviral vectors, adena-associated virus vectors, retroviral vectors, and the like.
The term "variant" in relation to the amino acid sequence
of the ETS transcription factors refers to a naturally occurring allelic variant of the ETS transcription factors such as
those shown in SEQ ID N0:07 and SEQ ID N0:08, which
includes any substitution of, variation of, modification of,
replacement of, deletion of or addition of one (or more)
amino acids provided the resultant ETS transcription factor
has a transcription factor activity and has a DNA binding
domain that is at least 85% identical to SEQ ID N0:01 or
SEQ ID N0:02 over the entire length of either of these
sequences. For example, a variant of ETS transcription
factor may have at least 50%, or at least 60%, or at least 70%
sequence identity with the ETS transcription factors such as
those shown in SEQ ID N0:07 and SEQ ID N0:08 over the
entire length of the sequence, provided that the variant has

4673-4680; Higgins eta!., (1996), Meth. Enzymol. 266:383402; Altschul et a!., (1993), Nature Genetics 3:266-272;
Brutlag et a!. (1990) Camp. App. Biosci. 6:237-24], the
disclosures of which are incorporated by reference in their
entireties. In an embodiment, protein and nucleic acid
sequence identities are evaluated using the Basic Local
Alignment Search Tool ("BLAST") which is well known in
the art [e.g., Karlin and Altschul, (1990), Proc. Nat!. Acad.
Sci. USA 87:2267-2268; Altschul eta!., (1997), Nuc. Acids
Res. 25:3389-3402] the disclosures of which are incorporated by reference in their entireties.
As used herein, an "oligonucleotide substrate" in reference to a substrate of a target ETS transcription factor refers
to an oligonucleotide which comprises a target ETS transcription factor binding site. An oligonucleotide substrate
can be single-stranded, double-stranded, or a hairpin. Preferably, an oligonucleotide substrate is double stranded. An
oligonucleotide substrate can be DNA, RNA or a chimeric
(comprising both deoxy and ribose nucleotides) or comprise
one or more oligonucleotide modifications described herein.
As used herein, the term "transcription factor binding
site" refers to a nucleic acid sequence that is recognized and
bound by a transcription factor and mediates the transactivation of a reporter gene in response to that binding. Without
limitations, a transcription binding site can be from any of
various species including human, mouse, rat, guinea pig and
the like. In some embodiments, the transcription factor
binding site is a target ETS binding site such as a FLil
binding site or an ERG binding site.
The MTM SA derivatives of the subject technology can
be synthesized according to the methods described below.
The inactivation of the mtmW gene, which is the gene
encoding the last acting enzyme in the MTM biosynthetic
pathway, produced MTM analogues with a short side chain
ketone (SK) and MTM with a short side chain diketone
(SDK) (FIG. 1). Both of these analogues possess shorter side
chains at the 3-position. The 3-side chain has been identified
previously as important, since it is in part responsible for
MTM's interaction with the DNA phosphate backbone. See
U.S. Pat. No. 7,423,008. Both MTM SK and MTM SDK
showed increased activity against several cancer cell lines
compared to the parent MTM. These results indicate that the
3-side chain is important for the activity of MTM and offers
a base for further molecular manipulations. As an unwanted
side product along with the production of the desired MTM
SK and MTM SDK analogues, MTM side chain carboxylic
acid (SA) is also accumulated in the MtmW-minus-mutant,
but showed in contrast to MTM SK and MTM SDK significantly decreased activity compared to MTM.
MTA SA is shown in formula (I) below:

~o!~f~c{~~ii~natff~~~{ 8~~:~!~yle=~d9g;:, a~ 1~~~5~n~!~~
least 98% identical to SEQ ID NO:Ol or SEQ ID N0:02
over the entire length of either of these sequences.
The terms "percentage of sequence identity" or "percentage homology" and any equivalent terms are used interchangeably herein to refer to comparisons among polynucleotides and polypeptides, and are determined by comparing
two optimally aligned sequences over a comparison window, wherein the portion of the oligonucleotide or polypeptide sequence in the comparison window may comprise
additions or deletions (i.e., gaps) as compared to the reference sequence (which does not comprise additions or deletions) for optimal alignment of the two sequences. The
percentage is calculated by determining the number of
positions at which the identical nucleic acid base or amino
acid residue occurs in both sequences to yield the number of
matched positions, dividing the number of matched positions by the total number of positions in the window of
comparison and multiplying the result by 100 to yield the
percentage of sequence identity. Identity is evaluated using
any of the variety of sequence comparison algorithms and
programs known in the art. Such algorithms and programs
include, but are by no means limited to, TBLASTN,
BLASTP, PASTA, TFASTA, CLUSTALW, FASTDB [Pearson and Lipman, (1988), Proc. Nat!. Acad. Sci. USA 85(8):
2444-2448; Altschul eta!., (1990), J. Mol. Bioi. 215(3):403410; Thompson et a!. (1994), Nucleic Acids. Res. 22(2):
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One reason for MTM-SA's decreased activity might be
that its 3-side chain is too short and its negatively charged
carboxylic acid does not sufficiently interact with naturally
negatively charged DNA. To overcome these potential deficiencies, a semi-synthetic approach was used herein to
chemically modifY the unique carboxylic acid moiety of
MTM SA to introduce new functionalities into the 3-side
chain. In one aspect of the present disclosure, the MTM SA
derivatives have the following formula:

thesis. ChemBioChem 2008, 9 (14), 2295-2304; (c) Nunez,
L. E.; Nybo, S. E.; Gonzalez-Sabin, J.; Perez, M.; Menendez, N.; Braiia, A. F.; He, M.; Moris, F.; Salas, J. A.; Rohr,
J.; Mendez, C., A Novel Mithramycin Analogue with High
Antitumor Activity and Less Toxicity Generated by Combinatorial Biosynthesis. J. Med. Chern. 2012, 55, 58135825; (d) Remsing, L. L.; Garcia-Bernardo, J.; Gonzalez, A.
M.; Kunze!, E.; Rix, U.; Braiia, A. F.; Bearden, D. W.;
Mendez, C.; Salas, J. A.; Rohr, J., Ketopremithramycins and
ketomithramycins, four new aureolic acid-type compounds
obtained upon inactivation of two genes involved in the
biosynthesis of the deoxysugar moieties of the antitumor
drug mithramycin by Streptomyces argillaceus, reveal novel
insights into post-PKS tailoring steps of the mithramycin
biosynthetic pathway. J. Am. Chern. Soc. 2002, 124 (8),
1606-1614; (e) Remsing, L. L.; Bahadori, H. R.; Carbone,
G. M.; McGuffie, E. M.; Catapano, C. V.; Rohr, J., Inhibition
of c-src transcription by mithramycin: structure-activity
relationships ofbiosynthetically produced mithramycin analogues using the c-src promoter as target. Biochemistry
2003, 42 (27), 8313-8324. Pharmaceutically acceptable salts
of the MTM SA derivative are also contemplated by the
present disclosure.
Preferably, Z represents NH, 0, or S and R represents
alkyl, aryl, heterocyclic, heteroaryl, etc., and when ZR is
taken together, ZR represents an amino acid conjugate or its
ester (e.g., a methyl ester). In certain embodiments, the
MTM SA derivative is an amide derivative, e.g. ZR together
form a NR 1 R 2 group where R 1 and R 2 can be the same or
different and each of R 1 and R 2 can be an H, alkyl, or an
amino acid conjugate or an ester derivative thereof. In other
embodiments, the MTM SA derivative is an amino acid
derivative, e.g. NR 1 R 2 together form an amino acid conjugate or an ester derivative thereof which can be further
substituted.
Previous work by Preobrazhenskaya et a!. (References
numbered 26-28) on olivomycin derivatizations showed that
introduction of N-atoms can improve aureolic acid type
anticancer drugs. The inventors discovered that MTM SA
derivatives with N -atoms can have improved efficacy. In one
embodiment of the present disclosure, MTM SA is derivatized with an amine to form an amide. Such MTM SA amide
derivatives advantageously have an elongated 3-side chain
and one or more N-atom/s, which can enhance the interaction of the derivative with the DNA-phosphate backbone
resulting in improved efficacy. In one aspect of the present
disclosure, the MTM SA derivative is provided by formula
(IV) below:
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where Z represents 0, S, N-R'; R and R' represent, for
each occurrence, H, alkyl, e.g., lower straight chain or
branched alkyl, heterocyclic, aryl, e.g., phenyl, naphthyl,
heteroaryl, e.g., pyridyl, pyrolidyl, piperidyl, pyrimidyl,
indolyl, thienyl, provided that R is not H when Z is 0; ZR
taken together represents an organic residue, e.g., an alkyl,
e.g., lower straight chain or branched alkyl, heterocyclic,
aryl, e.g., phenyl, naphthyl, heteroaryl, e.g., pyridyl,
pyrolidyl, piperidyl, pyrimidyl, indolyl, thienyl, an amino
acid conjugate or its ester derivative, e.g., proline (Pro),
alanine (Ala), serine (Ser), cysteine (Cys), histidine (His),
tryptophan (Trp ), tyrosine (Tyr), phenylalanine (Phe) conjugate, etc., a sugar or sugar chain. Each of the alkyl,
heterocyclic, aryl, heteroaryl, sugar, or sugar chain of R, R'
and ZR can be unsubstituted or substituted with one or more
amino, alkyl amino, alkylcarboxyl, alkoxyl, alkylcarbonyl,
hydroxyl, thio, alkyldisulfide, heterocyclic, aryl, heteroaryl,
halo, e.g., fluoro, chloro, bromo, iodo, an amino acid conjugate, ether, ester, amide residue, etc. The group MTM 1
represents the fused ring portion of the mithramycin structure and can include different sugars or sugar chains. In other
words, MTM 1 represents the structure of formula III below,
but also variants with different sugar patterns.
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Thus, the A, B, C, D, E, sugars can be different from those
shown, and include chain variants. Such sugars are disclosed, for example, in: (a) Baig, I.; Perez, M.; Braiia, A. F.;
Gomathinayagam, R.; Damodaran, C.; Salas, J. A.; Mendez,
C.; Rohr, J., Mithramycin analogues generated by combinatorial biosynthesis show improved bioactivity. J. Nat.
Prod. 2008, 71 (2), 199-207; (b) Perez, M.; Baig, I.; Braiia,
A. F.; Salas, J. A.; Rohr, J.; Mendez, C., Generation of new
derivatives of the antitumor antibiotic mithramycin by altering the glycosylation pattern through combinatorial biosyn-
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where R 1 and R 2 can be the same or different and each ofR 1
and R 2 can be an H, an amino acid conjugate or ester thereof,
a lower straight chain or branched alkyl unsubstituted or
substituted with one or more amino, alkyl amino, alkylcarboxyl, alkoxyl, alkylcarbonyl, hydroxyl, thio, alkyldisulfide,
halo, e.g., fluoro, chloro, bromo, iodo, provided that R 1 and
R 2 are not both H simultaneously. The amino acid conjugate
and ester derivatives that can be included in formula (V),
e.g., where NR 1 R 2 form an amino acid conjugate or ester
derivative thereof, include, for example, a proline (Pro, or
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0-alkyl-Pro ), alanine (Ala, or 0-alkyl-Ala), serine (Ser, or
0-alkyl-Ser), cysteine (Cys, or 0-alkyl-Cys), histidine (His,
or 0-alkyl-His), tryptophan (Trp, or 0-alkyl-Trp), tyrosine
(Tyr, or 0-alkyl-Tyr), and phenylalanine (Phe, or 0-alkylPhe) conjugate. Further, the amino acid conjugate or its
derivative can be substituted, e.g., substituted with -R3 Y
where R3 is alkyl, e.g., C 1 _16 or C 1 _8 alkyl, andY is a formyl,
ene, expoxy, aryl, e.g., phenyl, heteroaryl, e.g., indolyl,
group. In some embodiments -R3 Y together form an
allylox group. In some embodiments, the amino acid conjugate is phenylalanine (e.g., MTM SA-Phe) or an ester
derivative thereof or tryptophan (e.g., MTM SA-Trp) or its
ester derivative. Each of the MTM SA-Trp and MTM
SA-Phe and its ester derivatives can further be substituted,
e.g., substituted with -R3 Y.
In one embodiment of the present disclosure, the MTM
SA derivative is an amino acid derivative, i.e., at least one
of R 1 or R 2 is an amino acid conjugate, e.g., proline (Pro),
alanine (Ala), serine (Ser), cysteine (Cys), histidine (His),
tryptophan (Trp ), tyrosine (Tyr), conjugate. Preferably R 1 is
an amino acid conjugate and R 2 is H. For example, the MTM
SA derivative can be a MTM SA 0-Me-tryptophan derivative as shown in formula V below:

also neuroprotective and the MTM SA derivative can be
used to treat various neuro-diseases, such as Huntington
disease, etc.
The biosynthesis ofMTM SK and MTM SDK is accomplished through a genetically engineered S. argillaceus
strain, M7Wl, which contains an inactivated mtmW gene
coding for the MtmW enzyme. Both the MTM SK and MTM
SDK analogues have improved activity compared to the
parent MTM compound, thus it would be optimal if these
were the only two compounds produced by the M7Wl
strain. However, this is not the case, and two other major
compounds are produced alongside of MTM SK and MTM
SDK. One of these compounds, MTM SA, has previously
been disregarded as invaluable due to the relative lack of
biological activity compared to the parent compound. This is
unfortunate as MTM SA is produced in many fermentations
in higher amounts than MTM SK or MTM SDK, and the
production yield can be shifted even further in favor of the
production of MTM SA by altering the pH of the culture
media. Since MTM SK and MTM SDK are separated
chromatographically MTM SA is easily collected and isolated alongside MTM SK and MTM SDK during the normal
isolation procedure.
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FIG. 2 illustrates two different ways to produce the
starting material MTM SA and also shows various MTM SA
derivatives. In the figure, the MTM 1 group can include
different sugars or sugar chains, R represents a lower straight
chain or branched alkyl unsubstituted or substituted with one
or more amino, alkyl amino, alkylcarboxyl, alkoxyl, alkylcarbonyl, hydroxyl, thio, alkyldisulfide, halo other residues.
In addition, the NR 1 R 2 can form an amino acid conjugate or
ester derivative thereof as shown in FIG. 2. In one aspect of
the present disclosure, MTM SA amide derivatives can be
prepared by coupling the terminal carboxylic acid group of
MTM SA with an amine, e.g., a primary amine, to form the
MTM SA derivative.
Examples of particular MTM SA derivatives together
with their activity are provided in Table 2 in the Examples
section below. Additionally, other amino acid derivatives of
MTM SA can be prepared. For example, tryptophan can be
substituted on the MTM SA derivative. The MTM SAtryptophan derivative can be prepared the same way as the
other amino acid derivatives, only using Tryptophan-0methyl ester. OMe-Phe, OMe-Tyr and OMe-His derivatives
can be prepared in the same manner.
The MTM SA derivatives of the present disclosure can be
used for the treatment of cancer, such as brain, colon,
prostate, lung, breast, esophageal, pancreatic, skin, Ewing
sarcoma, any type of blood cancer etc. MTM derivatives are

45

50

55

60

65

An aspect of the present disclosure involves targeting the
3-side chain of MTM SA to form useful MTM SA derivatives. It is known that the 3-side chain of the MTM structure
is responsible for an interaction with the DNA-phosphate
backbone. Thus by altering the functionality of the 3-side
chain the specificity for the DNA of diseased cells can be
improved. The 3-side chain of MTM SA is terminated by a
carboxyl acid functional group which is likely ionized at a
physiological pH, repulsing from the negative charge of the
DNA phosphate backbone thereby weakening MTM SA's
ability to bind to the DNA.
In one aspect of the present disclosure, side chain functionalizations were rationally selected to contain cationic
amine residues in order to enhance the interaction with the
DNA phosphate backbone.
Screening Methods
The assay described herein provides a rational development and identification scheme for novel and potent MTM
analogues and derivatives with improved selectivity against
EWS-FLil. Without wishing to be bound by a theory, the
inventors have discovered inter alia that rather than displacing EWS-FLil from DNA, MTM binds DNA cooperatively
with EWS-FLil and hyperstabilizes it on the DNA (FIG. 4),
to disruption of its transcriptional functions residues in order
to enhance the interaction with DNA phosphate backbone.
Accordingly, in one aspect the subject technology provides a screening assay for identifying MTM SA derivatives
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as test compounds that selectively and specifically bind to
and modulate the activity of a target ETS transcription factor
such as EWS-FLI1 transcription factor. The assay includes
such steps as detecting the formation and/or stability of a
complex that includes (1) a target ETS transcription factor
that has a DNA binding domain with an amino acid sequence
that is at least 85% identical to SEQ ID N0:01 or SEQ ID
N0:02 over the entire length of either of these sequences, (2)
an oligonucleotide substrate and (3) the test compound.
In some embodiments, the subject technology provides a
method for screening mithramycin (MTM) derivatives
including MTM SA or a pharmaceutically acceptable salt
thereof for an ability to selectively complex with or modulate the activity of a target ETS transcription factor, said
method including the steps of (a) contacting the MTM SA
derivative with the target ETS transcription factor in the
presence of an oligonucleotide substrate; (b) assessing the
effect of the MTM SA derivative on the activity of the target
ETS transcription factor; and (c) selecting the MTM SA
derivative that has specificity for and/or modulates the
activity of the target ETS transcription factor relative to a
reference or control sample; wherein the target ETS transcription factor is Friend leukemia integration 1 transcription factor (FLil) or v-ets avian erythroblastosis virus E26
oncogene-like transcription factor (ERG). In some related
embodiments, the step (b) further includes assessing the
formation of a complex comprising the MTM SA derivative,
the target ETS transcription factor and the oligonucleotide
substrate. In some related embodiments, the step of assessing the formation of the complex is performed by crystallography. In some related embodiments, the specificity of
the test agent for the target ETS transcription is assessed by
detecting the formation and/or stability of a complex formed
between the target ETS transcription factor and its oligonucleotide substrate in the presence of the MTM SA derivative relative to a reference or control sample. In some related
embodiments, the specificity of the test agent for the target
ETS transcription is assessed by detecting the formation
and/or stability of a complex including the target ETS
transcription factor, the oligonucleotide substrate and the
MTM SA derivative. In some related embodiments, the
oligonucleotide substrate includes SEQ ID NOs:03-07. In
some related embodiments, the oligonucleotide substrate is
labeled with a detectable label. In some related embodiments, the MTM SA derivative or a pharmaceutically
acceptable salt thereof is a compound described herein.
MTM SA-Phe is an exemplary MTM SA derivative that
selectively and specifically binds to a target ETS transcription factor such as EWS-FLil is MTM SA-Phe which forms
a ternary MTM SA-Phe:EWS-FLil:DNA substrate complex
that hyperstabilizes the transcription factor to its binding
site, thus, perturbing the normal function of the transcription
factor. Another such example is MTM SA-Trp.
According to some embodiments of the subject technology, the amount or stability of the complex in the presence
of a test compound such as an MTM SA derivative is
determined relative to a control or reference sample. A
statistically significant increase in stability is indicative of an
increase in the formation of the complex or an increase in the
specificity of the test compound for the transcription factor.
A control or reference sample can be one or more of a
sample not exposed to the test compound; a sample exposed
to known inhibitor of the target ETS transcription factor
(e.g., FLil or ERG); a sample containing one or more other
ETS transcription factors capable competing with the target
ETS transcription factor for forming a complex with the test
compound; a sample exposed to a known inhibitor of the

complex; a sample containing a compound that may compete with the test compound to complex with the target ETS
transcription factor; or a sample exposed to an excess
amount of a labeled or an unlabeled binding member of the
complex. Methods of determining formation and/or stability
of the complex are described below.
According to some embodiments, the interactions
between a target ETS transcription factor, its oligonucleotide
substrate and an MTM SA derivative is fine-tuned by proper
chemical modification of the MTM SA derivative to increase
the specificity of the derivative for the target transcription
factor. In some embodiments, the MTM SA derivative of the
subject technology, while having high specificity for a target
ETS transcription factor such as FLI1, will not displace the
Sp transcription factors from the GC-rich promoter DNA. In
the case of Ewing sarcoma, where the target ETS transcription factor is EWS-FLil, the MTM SA derivative of the
subject technology selectively complexes with and inhibits
the activity of the EWS-FLil transcription factor and, thus,
is a potent and selective anti-Ewing sarcoma therapy.
A variety of assay formats can be used and, in light of the
present disclosure, those not expressly described herein will
nevertheless be understood to be included by one of ordinary
skill in the art. Screening methods or assay formats which
approximate such conditions as formation of a ternary
complex of a target ETS transcription factor (e.g., FLI1 or
ERG):oligonucleotide substrate:MTM SA derivative can be
generated in many different forms, and include assays based
on cell-free systems, e.g., purified peptides and oligonucleotides or cell lysates, as well as cell based assays which
utilize intact cells and in vivo assays.
The components of the complex can be added simultaneously to the assay sample, e.g., a reaction mixture or they
can be added sequentially in any order, e.g., forming a
mixture of the first component with a second component,
adding the third component forming a mixture of the first,
second, and third component, and adding the fourth component. In some embodiments, some components of the
complex are added sequentially while others are added
simultaneously, e.g., forming a reaction mixture with a first
component with a second component and adding the third
and fourth component simultaneously to the mixture, or
adding a first component followed by simultaneous addition,
e.g., a reaction mixture, of the rest of the components.
Assaying in the presence and absence of a test compound
can be accomplished in any vessel suitable for containing
the reactants. Examples include microtitre plates, test tubes,
and micro centrifuge tubes. Alternatively, the sample can
include cells in culture, e.g., purified cultured or recombinant cells, or in vivo in an animal subject.
In some embodiments, the screening assays can be performed in vitro using isolated/purified complex components.
In such a system, each component of the screen can be added
separately in wells of a multi-well plate. In some embodiments, the multimeric complex will be allowed to form prior
to the addition of the test compound to be screened. In other
embodiments, the members of the complex and the test
agent will be added together, e.g., at the same time or
simultaneously, with one or more of the members of the
complex.
Complex components can be used at any concentration
suitable for the assay conditions being used, e.g., size of the
reaction vessel, time limitations, detection limits, amount of
the limiting component, etc. Additionally, amount of the
various components of the complex can be the same, all
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different, or combinations thereof. Generally, amount of
3x, at least 4x, at least 5x or more relative to the amount of
each component is within 15% to 5% of the amount of each
another complex component. In some embodiments, the
competitor is present in an amount which is at least 0.1x, at
of the other components.
In some embodiments, the concentration of each of the
least 0.2x, at least 0.3x, at least 0.4x, at least 0.5x, at least
0.6x, at least 0.7x, at least O.Sx, at least 0.9x, at least 1x, at
complex components in the assay sample is independently
from about 0.01 nM to about 1.0 mM. In some embodileast 1.25x, at least 1.5x, at least 1.75x, at least 2x, at least
2.5x, at least 3x, at least 4x, at least 5x or more relative to
ments, the concentration of each of the complex components
is independently from about 0.1 nM to about 100 f.LM, from
the amount of the complex component being competed
about 0.5 nM to about 50 f.LM, or from about 1 nM to about
against.
Any suitable buffer/media/solvent can be used in the
25 f.LM. In some embodiments, the concentration of each of 10
the complex component is independently from about 10 nM
screening assay. Exemplary buffers include, but are not
to about 40 f.LM. In one embodiment, the concentration of
limited to, phosphate buffered saline (PBS), sodium phoseach of the complex components is about 10 nM, or about
phate, sodium sulphate, Tris buffers, Tris-HCl buffers, gly20 nM, or about 50 nM, or about 100 nM, or about 250 nM,
cine buffer, and sterile water. The buffer can be present in the
or about 1 f.LM. In one embodiment, concentration of each of 15 assay sample at any suitable concentration. Typically, the
assay sample comprises a buffer in a concentration of about
the complex component is greater than 20 nM.
The assay sample volume depends on the particular setup
5-100 mM. In some embodiments, the assay sample combeing used for the screening assay. Generally, the assay
prises a buffer in a concentration of about 5-75 mM (e.g., 10
sample has a final volume of about 10 nl to about 1 mi. In
mM, 20 mM, 25 mM, 30 mM, 35 mM, 40 mM, 45 mM, or
some embodiments, the final volume of the sample assay is 20 50 mM). Generally, the buffer has a pH of from about 5 to
from about 1 ml to about 100 mi. In addition to the complex
about 10. In some embodiments, the buffer has a pH of from
components, a variety of other reagents can be included in
about 6 to about, from about 6.5 to about 8, or from 6.5 to
the screening assay samples. These include reagents like
about 7.5. The pH of the buffer can be adjusted by addition
of any suitable acid or base (e.g., HCl). In some embodisalts, neutral proteins, e.g., albumin, detergents, etc. that are
used to facilitate optimal protein-protein binding and/or 25 ments, the sample buffer is 20 mM Tris pH 7.5, 50 mM
NaCl, 5% glycerol, 0.5 mg/ml BSA.
reduce nonspecific or background interactions. Reagents
that improve the efficiency of the assay, such as protease
Formation and/or stability of the complex can be assayed
inhibitors, single stranded nuclease inhibitors, anti-microat any suitable temperature. Accordingly, in some embodiments, the formation and/or stability of the complex is
bial compounds are also included. The mixture of components is added in any order that provides for the requisite 30 assayed at a temperature in the range of about 15° C. to
about 65° C. In some embodiments, the formation and/or
assembly of the complex.
stability of the complex is assayed at a temperature in the
In some embodiments, the assay sample comprises a
range of about 15° C. to about 45° C. In some embodiments,
competitor of at least one component of the complex. The
term "competitor of a component of the complex" refers to
the formation and/or stability of the complex is assayed at a
a compound or composition that competes with said com- 35 temperature in the range of about 15° C. to about 25° C.
ponent for binding with another component of the complex.
After all of the reagents have been added, evaluation of
the complex formation or stability can be done right away,
For example, an unlabeled complex component can be
e.g., within 5 minutes of addition of last reagent, or after a
considered a competitor of the labeled component. In
period of time has elapsed after addition of the last reagent.
another example, an oligonucleotide comprising either a
target ETS transcription factor binding site or a transcription 40 In some embodiments, the sample assay is allowed to
incubate for at least 5 minutes, at least 10 minutes, at least
binding site is a competitor of the oligonucleotide substrate
of the target ETS transcription factor. In some embodiments,
15 minutes, at least 20 minutes, at least 25 minutes, at least
the competitor is another ETS transcription factor other
30 minutes, at least 35 minutes, at least 40 minutes, at least
than, for example, a FLI1 or ERG. In another embodiment,
45 minutes, at least 1 hour, at least 2 hours, at least 5 hours
the competitor is an MTM SA derivative other than the one 45 or more before evaluating the complex formation or stabilbeing assayed.
ity. In one embodiment, the assay sample is allowed to
The amount of a competitor of a component of the
incubate for 30 minutes after addition of the last reagent
complex in the sample assay can be adjusted to optimize the
before evaluating the complex formation or stability.
The assays of the subject technology can be used to
detection of the assay. Accordingly, in some embodiments,
concentration of the competitor in the assay sample is from so evaluate and/or detect a change in complex formation and/or
about 0.01 nM to about 1000 nM. In some embodiments,
complex stability by detecting one or more of (1) a change
amount of the competitor in the assay sample is from about
in the binding or physical formation of the complex itself,
e.g., by biochemical detection, affinity based detection (e.g.,
0.1 nMto about 100 f.LM, from about 0.5 nMto about 50 f.LM,
Western blot, affinity columns), immunoprecipitation, fluoor from about 1 nM to about 25 f.LM. In some embodiments,
amount of the competitor in the assay sample is from about 55 rescence resonance energy transfer (FRET)-based assays
10 nM to about 20 f.LM. In some embodiments, amount of the
(e.g., FRET or Time Resolved FRET (TR-FRET) assays),
competitor in the assay sample is from about 150 nM to
surface plasmon resonance (SPR), spectrophotometric
about 250 nM. In one embodiment, concentration of the
means (e.g., circular dichroism, absorbance, and other meacompetitor in the assay sample is about 10 nM, about 20 nM,
surements of solution properties); (2) an increase or a
or about 200 nM.
60 decrease, in signal transduction, e.g., phosphorylation and/or
The amount of a competitor of a component of the
transcriptional activity; (3) an increase or decrease in cell
complex in the sample assay can be relative to any other
function. All of these methods are known in the art.
component of the complex. For example, the competitor can
In some embodiments, the screening assay is a highthroughput screening assay. HTS is a relative term, but is
be present in an amount which is at least 0.1x, at least 0.2x,
at least 0.3x, at least 0.4x, at least 0.5x, at least 0.6x, at least 65 generally defined as the testing of 10,000 to 100,000 com0.7x, at least O.Sx, at least 0.9x, at least 1x, at least 1.25x,
pounds per day, accomplished with mechanization that
at least 1.5x, at least 1.75x, at least 2x, at least 2.5x, at least
ranges from manually operated workstations to fully auto-
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mated robotic systems using robotics, data processing and
control software, liquid handling devices, and sensitive
detectors.
Methods of Treatment
In one aspect, the subject technology provides a method
for selectively modulating the activity of a target ETS
transcription factor in a patient in need thereof, including
administering to the patient a therapeutically effective
amount of an MTM SA derivative or a pharmaceutically
acceptable salt thereof having the following formula:

In other embodiments relating to this aspect, the MTM SA
derivative is MTM SA-Phe or MTM SA-Trp and the target
ETS transcription factor being selectively modulated is FLI 1
and/or ERG. In other embodiments relating to this aspect,
the MTM SA derivative is MTM SA-Phe or MTM SA-Trp
which further include one or more different sugar groups
such as D-digitoxose and the target ETS transcription factor
being modulated is FLil and/or ERG. In other embodiments, administration results in modulation of the activity of
the ETS transcription factor in the patient. In other embodiments, the target ETS transcription factor is Friend leukemia
integration 1 transcription factor (FLil) or v-ets avian
erythroblastosis virus E26 oncogene like transcription factor
(ERG).
In another aspect, the subject technology provides a
method of treating a target ETS transcription factor-mediated disease in a patient by administering to the patient a
therapeutically effective amount of an MTM SA-Phe, MTM
SA-Trp or any other MTM SA derivative described herein,
wherein the MTM SA derivative specifically modulates the
activity of the ETS transcription factor mediating the disease
and wherein the target ETS-mediated disease is Ewing
sarcoma, clear-cell sarcoma, myxoid liposarcoma, desmoplastic small round cell tumor, myxoid chondrosarcoma,
acute myeloid leukemia, congenital fibrosarcoma, prostate
cancer or pancreatic cancer, for example. Table 1 below lists
several ETS transcription factors that may be modulated and
associated diseases that may be treated with the subject
technology.
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wherein Z represents 0, S, N-R'; R and R' represent, for
each occurrence, H, alkyl, heterocyclic, aryl, heteroaryl,
provided that R is not H when Z is 0; ZR taken together
represents an organic residue; and wherein MTM 1 represents
the fused ring portion of the mithramycin structure and can
include different sugars or sugar chains. In addition, Z and
R can represent all of the various embodiments described
herein including when ZR together form an amide, amino
acid conjugate or ester derivative thereof, etc.
In an embodiment relating to this aspect, the subject
technology provides a method for selectively modulating the
activity of a target ETS transcription factor in a patient with
Ewing sarcoma or prostate cancer for example. The method
includes administering to the patient a therapeutically effective amount ofMTM SA-Phe or MTM SA-Trp, or a derivative thereof, for example. In some embodiments relating to
this aspect, the ETS transcription factor includes a DNA
binding domain with an amino acid sequence that is at least
85% identical to SEQ ID NO:Ol or SEQ ID N0:02 over the
entire length of either of these sequences. In other embodiments relating to this aspect, ZR together represents an
NR 1 R 2 group, e.g., an amino acid conjugate or an ester
derivative thereof. In certain embodiments, NR 1 R 2 is the
amino acid conjugate is an aromatic amino acid conjugate,
e.g., phenylalanine, tryptophan or an ester derivative
thereof. The amino acid conjugate or ester derivative thereof
can further be substituted. Substituents include, for example,
-R3 Y where R 3 is alkyl, e.g., C 1 _16 or C 1 _8 alkyl, andY is
a formyl ene, expoxy, aryl, e.g., phenyl, heteroaryl, e.g.,
indolyl. In some embodiments -R3 Y together form an
allylox group. In other embodiments relating to this aspect,
the MTM SA derivative includes one or more sugar groups
such as D-digitoxose. In other embodiments relating to this
aspect, the MTM SA derivative is MTM SA-Phe or MTM
SA-Trp and the target ETS transcription factor being selectively modulated is FLil and/or ERG. In other embodiments
relating to this aspect, the MTM SA derivative is MTM
SA-Phe which further includes one or more different sugar
groups such as D-digitoxose and/or an indole ring on the
phenylalanine and the target ETS transcription factor being
modulated is FLil and/or ERG. In other embodiments, the
MTM SA derivative is MTM SA-Phe-Allylox and the target
ETS transcription factor being selectively modulated is FLI 1
and/or ERG. In other embodiments relating to this aspect,
the MTM SA derivative is MTM SA-Phe-Allylox which
further includes one or more different sugar groups such as
D-digitoxose and the target ETS transcription factor being
modulated is FLil and/or ERG.
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TABLE 1
ETS Transcription factors and associated diseases.

35 Transcription factor

ETS-1

40

ETS-2
ERG

FLil
PEA3
ER81
45
ELF-1
TELIETV6
PU.1/SPI1
50 Myc
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Disease
Meningioma, invasive carcinoma of the breast,
colorectal carcinoma, pancreatic carcinoma,
adenocarcinoma, thyroid carcinoma, thymoma,
angioma
Breast cancer
TMPRSS2:ERG fusion in prostate cancer
EWS-ERG fusion in Ewing Sarcoma
ERG overexpression in AML
EWS-FLil fusion in Ewing Sarcoma
Invasive breast carcinoma
EWS-ER81 fusion in Ewing sarcoma, prostate
carcinoma, breast carcinoma
Prostate, ovarian and breast cancers, leukemia
and lymphoma.
TEL fusion protein partners (PDGFbetaR, TRK.c,
ABL, and JAK2) in leukemia and fibrosarcoma
Promyelocytic leukemia, acute myelocytic leukemia
Burkitt lymphoma, B-celllymphoma, multiple
myeloma, medulloblastoma, neuroblastoma,
colorectal, ovarian and intestinal cancer

The target ETS transcription factor specifically modulated
may be FLil transcription factor or ERG transcription
factor. In an embodiment of this aspect, a therapeutically
effective amount of MTM SA-Trp or MTM SA-Phe or a
derivative or salt thereof is administered to a Ewing sarcoma
patient. In other embodiments, a therapeutically effective
amount ofMTM SA-Trp or MTM SA-Phe or a derivative or
salt thereof is administered to a patient with any of the
diseases listed in Table 1.
In general, the MTM SA derivatives of the present disclosure can be used for the treatment of a target ETS
transcription factor-mediated disease including Ewing sarcoma, clear-cell sarcoma, myxoid liposarcoma, desmoplastic small round cell tumor, myxoid chondrosarcoma, acute
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myeloid leukemia, congenital fibrosarcoma, prostate cancer,
pancreatic cancer, acute myeloid leukemia (AML), acute
lymphoblatic leukemia (ALL), Alzheimer's disease (AD), or
Down syndrome (DS) or other hyperproliferative disease in
which an aberrant activity of a target ETS transcription
factor is implicated. A "hyperproliferative disease" includes
diseases and conditions that are associated with any sort of
abnormal cell growth or abnormal growth regulation, specifically a cancer.
In certain embodiments, the present disclosure provides a
method of treating a hyperproliferative disease mediated by
an aberrant activity of a target ETS transcription factor
comprising administering to a subject in need thereof a
therapeutically effective amount of a composition comprising an MTM SA derivative such that the activity of the target
transcription factor is reduced or inhibited; wherein the
MTM SA derivative is MTM SA-Phe, MTM SA-Trp, MTM
SA-Ala, MTM SA-Tyr or MTM SA-Phe-Allylox and
wherein the target ETS-mediated disease is Ewing sarcoma,
clear-cell sarcoma, myxoid liposarcoma, desmoplastic small
round cell tumor, myxoid chondrosarcoma, acute myeloid
leukemia, congenital fibrosarcoma, prostate cancer or pancreatic cancer. In certain other embodiments, the present
disclosure provides a method of treating Ewing sarcoma
comprising administering to a subject in need thereof a
therapeutically effective amount of a composition comprising an MTM SA derivative selected from the group consisting of MTM SA-Phe, MTM SA-Trp, MTM SA-Ala,
MTM SA-Tyr, MTM SA-Phe-Allylox or a derivative
thereof, wherein the derivative comprises one or more sugar
groups comprising digitoxos or other derivative described
herein. In an embodiment of this aspect, the target ETS
transcription factor specifically modulated is Friend leukemia integration 1 transcription factor (FLil) or v-ets avian
erythroblastosis virus E26 oncogene-like transcription factor
(ERG). In an embodiment, the present disclosure provides a
method of treating a hyperproliferative disease mediated by
an aberrant activity of a target ETS transcription factor
comprising administering to a subject in need thereof a
therapeutically effective amount of a composition comprising MTM SA-Phe and/or MTM SA-Phe allylox or comprising MTM SA-Trp such that the activity of the target transcription factor is reduced or inhibited; wherein the ETS
target transcription factor is FLil or ERG.
As described above, the screening method of the subject
technology identifies MTM SA derivatives that are more
specific than MTM for complexing with a target EST
transcription factor and, therefore, inhibiting its activity. The
specific or selective MTM SA derivatives of the subject
technology are useful for treating diseases that are mediated
by, for example, FLil or ERG, such as Ewing sarcoma,
clear-cell sarcoma, myxoid liposarcoma, desmoplastic small
round cell tumor, myxoid chondrosarcoma, acute myeloid
leukemia, congenital fibrosarcoma, prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), acute lymphoblatic leukemia (ALL), Alzheimer's disease (AD), or Down
syndrome (DS) or other hyperproliferative disease in which
an aberrant activity of a target ETS transcription factor is
implicated.
Other hyperproliferative diseases which may be benefited
by the methods and compounds of the subject technology
include, though it is not limited to, neoplasm, malignant;
carcinoma; carcinoma, undifferentiated; giant and spindle
cell carcinoma; small cell carcinoma; papillary carcinoma;
squamous cell carcinoma; lymphoepithelial carcinoma;
basal cell carcinoma; pilomatrix carcinoma; transitional cell
carcinoma; papillary transitional cell carcinoma; adenocar-

cinoma; gastrinoma, malignant; cholangiocarcinoma;
hepatocellular carcinoma; combined hepatocellular carcinoma and cholangiocarcinoma; trabecular adenocarcinoma;
adenoid cystic carcinoma; adenocarcinoma in adenomatous
polyp; adenocarcinoma, familial polyposis coli; solid carcinoma; carcinoid tumor, malignant; branchiolo-alveolar
adenocarcinoma; papillary adenocarcinoma; chromophobe
carcinoma; acidophil carcinoma; oxyphilic adenocarcinoma; basophil carcinoma; clear cell adenocarcinoma;
granular cell carcinoma; follicular adenocarcinoma; papillary and follicular adenocarcinoma; nonencapsulating sclerosing carcinoma; adrenal cortical carcinoma; endometroid
carcinoma; skin appendage carcinoma; apocrine adenocarcinoma; sebaceous adenocarcinoma; ceruminous adenocarcinoma; mucoepidermoid carcinoma; cystadenocarcinoma;
papillary cystadenocarcinoma; papillary serous cystadenocarcinoma; mucinous cystadenocarcinoma; mucinous
adenocarcinoma; signet ring cell carcinoma; infiltrating duct
carcinoma; medullary carcinoma; lobular carcinoma;
inflammatory carcinoma; paget's disease, mmary; acinar
cell carcinoma; adenosquamous carcinoma; adenocarcinoma w/squamous metaplasia; thymoma, malignant; ovarian stromal tumor, malignant; thecoma, malignant; granulosa cell tumor, malignant; androblastoma, malignant;
Sertoli cell carcinoma; Ieydig cell tumor, malignant; lipid
cell tumor, malignant; paraganglioma, malignant; extramammary paraganglioma, malignant; pheochromocytoma;
glomangiosarcoma; malignant melanoma; amelanotic melanoma; superficial spreading melanoma; malignant melanoma in giant pigmented nevus; epithelioid cell melanoma;
blue nevus, malignant; sarcoma; fibrosarcoma; fibrous histiocytoma, malignant; myxosarcoma; liposarcoma; leiomyosarcoma; rhabdomyosarcoma; embryonal rhabdomyosarcoma; alveolar rhabdomyosarcoma; stromal sarcoma; mixed
tumor, malignant; mullerian mixed tumor; nephroblastoma;
hepatoblastoma; carcinosarcoma; mesenchymoma, malignant; breunertumor, malignant; phyllodes tumor, malignant;
synovial sarcoma; mesothelioma, malignant; dysgerminoma; embryonal carcinoma; teratoma, malignant; struma
ovarii, malignant; choriocarcinoma; mesonephroma, malignant; hemangiosarcoma; hemangioendothelioma, malignant; kaposi's sarcoma; hemangiopericytoma, malignant;
lymphangiosarcoma; osteosarcoma; juxtacortical osteosarcoma; chondrosarcoma; chondroblastoma, malignant; mesenchymal chondrosarcoma; giant cell tumor of bone;
ewing's sarcoma; odontogenic tumor, malignant; ameloblastic odontosarcoma; ameloblastoma, malignant; ameloblastic
fibrosarcoma; pinealoma, malignant; chordoma; glioma,
malignant; ependymoma; astrocytoma; protoplasmic astrocytoma; fibrillary astrocytoma; astroblastoma; glioblastoma;
oligodendroglioma; oligodendroblastoma; primitive neuroectodermal; cerebellar sarcoma; ganglioneuroblastoma;
neuroblastoma; retinoblastoma; olfactory neurogenic tumor;
meningioma, malignant; neurofibrosarcoma; neurilemmoma, malignant; granular cell tumor, malignant; malignant
lymphoma; hodgkin's disease; hodgkin's; paragranuloma;
malignant lymphoma, small lymphocytic; malignant lymphoma, large cell, diffuse; malignant lymphoma, follicular;
mycosis fungoides; other specified non-hodgkin's lymphomas; malignant histiocytosis; multiple myeloma; mast cell
sarcoma; immunoproliferative small intestinal disease; leukemia; lymphoid leukemia; plasma cell leukemia; erythroleukemia; lymphosarcoma cell leukemia; myeloid leukemia;
basophilic leukemia; eosinophilic leukemia; monocytic leukemia; mast cell leukemia; megakaryoblastic leukemia;
myeloid sarcoma; and hairy cell leukemia.
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In another aspect of the present disclosure, an effective
amount of the MTM SA derivative or a pharmaceutically
acceptable salt thereof is administered to a patient in need of
cancer treatment or a neuro-disease, such as Huntington'd
disease. The MTM SA derivatives or pharmaceutically
acceptable salts thereof of the present disclosure can be
administered to a patient, e.g., a human patient, in need of
such treatment by any route. The MTM SA derivatives or
pharmaceutically acceptable salts thereof of the present
disclosure can be administered alone or with a pharmaceutically acceptable carrier or excipient.
Dosage Form and Formulation of MTM SA
An MTM SA derivative of the subject technology such as
MTM SA-Phe, MTM SA-Trp or a derivative thereof can be
administered to a patient in need thereof in any possible
dosage form including, but not limited to ingestible tablets,
buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, infusion, aqueous liquid and the like. Solutions
of an MTM SA such as MTM SA-Phe or MTM SA-Trp can
be prepared in water and mixed with suitable excipients.
Under ordinary conditions of storage and use, these preparations can contain a preservative to prevent the growth of
microorganisms or retain stabilization of the MTM SA
derivative. The pharmaceutical forms suitable for injection
include sterile aqueous solutions or dispersions and sterile
powders for the extemporaneous preparation of sterile
injectable solutions or dispersions. The form should be
sterile and should be fluid to the extent it makes injection
possible.
A composition containing an MTM SA derivative of the
disclosure such as MTM SA-Phe, MTM SA-Trp or a pharmaceutically acceptable salt thereof can be prepared by
known methods, such that an effective quantity of the
therapeutic agent is delivered to a subject. Suitable vehicles
for such a composition are described, for example, in
Remington's Pharmaceutical Sciences (2003) and in the
Handbook of Pharmaceutical Additives (compiled by
Michael and Irene Ash, Gower Publishing Limited, Aldershot, England (1995)).
In some embodiments, the composition of this disclosure
enables sustained, continuous delivery of an MTM SA
derivative such as MTM SA-Phe, MTM SA-Trp or a pharmaceutically acceptable salt thereof to tissues adjacent to or
distant from an administration site. The biologically-active
agent is capable of providing a local or systemic biological,
physiological or therapeutic effect. For example, MTM
SA-Phe or MTM SA-Trp may act to kill cancer cells or
cancer stem cells or to control or suppress tumor growth or
metastasis, among other functions.
In some embodiments, the formulations of the present
disclosure are administered in an amount effective to provide the desired level of biological, physiological, pharmacological and/or therapeutic effect such as inhibition of a
target ETS transcription factor.
The actual dosage amount of a composition of the present
disclosure administered to a patient or subject can be determined by physical and physiological factors such as body
weight, severity of condition, the type of disease being
treated, previous or concurrent therapeutic interventions,
idiopathy of the patient and on the route of administration.
The practitioner responsible for administration will, in any
event, determine the concentration of active ingredient( s) in
a composition and appropriate dose(s) for the individual
subject.
In certain embodiments, pharmaceutical formulations
include, for example, at least about 0.1% of an active
compound, such as MTM SA or derivatives thereof or

pharmaceutically acceptable salt thereof. In other embodiments, the active compound may comprise between about
1% to about 75% of the weight of the unit dosage, or
between about 5% to about 50% by weight of the unit
dosage, for example, and any specific percentage in between
these ranges. In other non-limiting examples, a dose may
also comprise from about 0.01 microgram/kg/body weight,
about 50 microgram/kg/body weight, about 100 microgram/
kg/body weight, about 500 microgram/kg/body weight,
about 1 milligram/kg/body weight, about 5 milligram/kg/
body weight, about 10 milligram/kg/body weight, about 30
milligram/kg/body weight, about 40 milligram/kg/body
weight, about 50 milligram/kg/body weight, about 100 milligram/kg/body weight, or more per administration, and any
range or specific amount derivable therein. In non-limiting
examples of a derivable range from the numbers listed
herein, a range of about 5 microgram/kg/body weight to
about 5 milligram/kg/body weight, about 50 microgram/kg/
body weight to about 50 milligram/kg/body weight, etc., can
be administered.
For a safe and effective dosage, the formulations can be
administered at an MTM SA derivative dose of about 0.01
to about 500 mg/m2 (body surface)/day, about 0.01 to about
300 mg/m2 /day, 0.01 to about 200 mg/m 2 /day, about 1 to
about 200 mg/m2 /day about 10 to about 100 mg/m2 /day,
about 25 to about 100 mg/m2 /day or any range derivable
therein to a subject such as a human. In certain aspects, the
composition may be administered at a dose of about 0.01 to
about 200 mg/kg body weight, about 0.01 to about 100
mg/kg body weight, 1 to about 50 mg/kg body weight, about
1 to about 20 mg/kg body weight, about 3 to about 10 mg/kg
body weight, about 3 to about 6 mg/kg body weight or any
range derivable therein to a subject such as a human. In some
embodiments, a formulation of the subject technology may
be administered in a dose of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15,
20, 25, 30, 40, 50, 60, 70, 80, 90, 100 mg or more per day.
Each liquid dose may be in a volume of 1, 10, 50, 100, 200,
500, 1000 or more fll or mi.
In some embodiments, the pharmaceutical formulation of
the subject technology includes an MTM SA derivative such
as MTM SA-Phe or MTM SA-Trp in an amount effective to
result in a serum concentration of the MTM SA in the
mammal in a range of from 1 nM to 1 mM, particularly 1 nM
to 2 f.LM.
Serum and systemic circulation concentrations of MTM
SA derivatives effective to result in the treatment of a target
ETS transcription factor-mediated disease may vary depending on a number of factors. Influential variables can include,
for example, pKa, solubility or molecular weight of the
MTM SA derivative. These properties of a particular MTM
SA derivative such as MTM SA-Phe or MTM SA-Trp may
affect how a patient metabolizes the compound, how much
of the compound enters and remains in the systemic circulation of the patient, and how effectively the compound
treats, prevents or causes regression of the disease, e.g.,
Ewing sarcoma, tumor or cancer.
Precise amounts of the therapeutic composition also
depend on the judgment of the practitioner and are peculiar
to each individual. Factors affecting the dose include the
physical and clinical state of the patient, the route of
administration, the intended goal of treatment (e.g. alleviation of symptoms versus cure) and the potency, stability and
toxicity of the particular therapeutic substance.
Route of Administration
In accordance with the methods of the disclosure, the
described composition or formulation of the subject technology may be administered to a subject in a variety of
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forms depending on the selected route of administration, as
will be understood by those skilled in the art. It may be
administered, for example, by oral, parenteral, buccal, sublingual, nasal, rectal, patch, pump, or transdermal administration and the pharmaceutical compositions formulated
accordingly. Parenteral administration includes intravenous,
intraperitoneal, subcutaneous, intramuscular, intratumoral,
transepithelial, nasal, intrapulmonary, intrathecal, rectal and
topical modes of administration. Parenteral administration
may be by continuous infusion over a selected period of
time.
Combination Therapies
In certain embodiments, the compounds, compositions or
formulations of the subject technology are administered with
a second or additional active agent(s) such as with one or
more different MTM SA derivatives or another anticancer
agent. Such therapy can be applied in the treatment of any
disease for which treatment with an MTM SA derivative
such as MTM SA-Phe or MTM SA-Trp is contemplated. For
example, the disease may be a hyperproliferative disease,
such as Ewing sarcoma or prostate cancer.
In certain embodiments, the additional active agent may
be a chemotherapeutic agent or a radiation therapy.
Examples of chemotherapeutic agents include, but are not
limited to, cetuximab (erbitux), herceptin (trastuzumab ),
fludarabine, cyclophosphamide, rituximab, imatinib, Dasatinib (BMS0354825), cisplatin (CDDP), carboplatin, procarbazine, mechlorethamine, camptothecin, ifosfamide,
melphalan, chlorambucil, busulfan, nitrosurea, dactinomycin, daunorubicin, doxorubicin, bleomycin, plicomycin,
mitomycin, etoposide (VP 16), tamoxifen, raloxifene, estrogen receptor binding agents, taxol, gemcitabien, navelbine,
farnesyl-protein tansferase inhibitors, transplatinum, 5-fluorouracil, vincristin, vinblastin, methotrexate, an analogue or
derivative thereof. In certain embodiments, the active or
anticancer agent(s) that may be used in combination with an
MTM SA derivative may be fludarabine, cyclophosphamide,
rituximab, imatinib or Dasatinib. In a certain aspect, the
cancer may be resistant to a particular chemotherapeutic
agent, such as fludarabine, cyclophosphamide, rituximab,
imatinib or Dasatinib.
Polypeptides
In some embodiments, the subject technology provides an
engineered ETS transcription factor comprising a DNA
binding domain of SEQ ID N0:01 or SEQ ID N0:02,
wherein the ETS transcription factor includes at least one
amino acid substitution at any of amino acid residues
corresponding to residues Tyr68, Lys75, His77, Gly78,
Lys79, Arg80, Tyr81, Ala82 of its DNA binding domain. In
some other embodiments, the subject technology provides
an engineered ETS transcription factor comprising a DNA
binding domain with an amino acid sequence that is at least
85% identical to SEQ ID NO:Ol or SEQ ID N0:02 over the
entire length of either of these sequences, and has at least
one amino acid substitution at any of the amino acid residues
of its DNA binding domain that correspond to residues
Tyr68, Lys75, His77, Gly78, Lys79, Arg80, Tyr81, Ala82 of
SEQ ID NO:Ol or SEQ ID N0:02.
The engineered ETS transcription factors of the subject
technology may be prepared in a number of ways that are
known by a person skilled in the art. For example, mutations
may be introduced by means of oligonucleotide-directed
mutagenesis or other conventional methods. Alternatively,
engineered ETS transcription factors may be generated by
site specific replacement of a particular amino acid with an
unnaturally occurring amino acid. This may be achieved by
growing a host organism capable of expressing either the

wild-type or mutant polypeptide on a growth medium
depleted of one or more natural amino acids but enriched in
one or more corresponding unnaturally occurring amino
acids. The expression or the activity (e.g., DNA binding) of
the engineered polypeptide may be determined using the
methods described in the Examples.
For increased stability and half-life, the engineered polypeptides of the subject technology may be modified by
chemical moieties and/or functional groups such as an
amine, carboxyl, thiol or hydroxyl group. See, e.g., Kochendoerfer eta!., Science, 299: 884-887 (2003) which is incorporated herein by reference in its entirety. Chemicals useful
in making such modifications include, but are not limited to,
polymers like polyethylene glycol (PEG), polypeptides such
as the Fe portion of an antibody or chemical groups. These
modifications will increase the stability and half-life of the
polypeptides of the subject technology.
Polynucleotides
Another aspect of the subject technology provides polynucleotide sequences encoding the engineered ETS transcription factors of the subject technology. Further included
in the subject technology are polynucleotides encoding the
engineered ETS transcription factors of the present disclosure that are fused in frame to the coding sequences for
additional heterologous amino acid sequences. Also
included are nucleic acids encoding the engineered ETS
transcription factors of the present disclosure together with
additional, non-coding sequences, including, but not limited
to, non-coding 5' and 3' sequences, vector sequence,
sequences used for purification, probing, or priming. For
example, heterologous sequences include transcribed,
untranslated sequences that may play a role in transcription
and mRNA processing, such as ribosome binding and stability of mRNA. The heterologous sequences may alternatively comprise additional coding sequences that provide
additional functionalities. Thus, a nucleotide sequence
encoding a polypeptide may be fused to a tag sequence, such
as a sequence encoding a peptide that facilitates purification
or detection of the fused polypeptide. In certain embodiments of this aspect of the subject technology, the tag amino
acid sequence is a hexa-histidine peptide (SEQ ID NO: 10),
such as the tag provided in a pQE vector (QIAGEN), or in
any of a number of additional, commercially available
vectors.
Polynucleotides of the subject technology will be generally at least 60% or 70%, preferably at least 80 or 90% and
more preferably at least 95% or 98% homologous to the
nucleotide sequences encoding an engineered ETS transcription factor described above, over a region of at least 20,
preferably at least 25 or 30, for instance at least 40, 60 or 100
or more contiguous nucleotides. Polynucleotides of the
subject technology will be capable of encoding an engineered ETS transcription factor with a DNA binding domain
comprising a DNA binding domain with an amino acid
sequence that is at least 85% identical to SEQ ID N0:01 or
SEQ ID N0:02 over the entire length of either of these
sequences and has at least one amino acid substitution at any
of amino acid residues corresponding to residues Tyr68,
Lys75, His77, Gly78, Lys79, Arg80, Tyr81, Ala82 of SEQ
ID N0:01 or SEQ ID N0:02.
Constructs
In another aspect of the subject technology, the coding
polynucleotide sequences encoding the engineered ETS
transcription factors of the subject technology may be operably linked to a promoter in a DNA construct using conventional cloning technology. The promoter may be a
homologous or a heterologous promoter, i.e., a promoter not
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natively associated with the coding sequence. The promoter
may be constitutive or inducible. Suitably, the promoter
includes an expression control sequence near the start site of
transcription. A promoter may include enhancer or repressor
elements that may be non-contiguous with the start site of
transcription. The polynucleotide may be provided within a
vector, for example, a plasmid, cosmid, or virus.
Kits
The subject technology also encompasses kits for assessing the effect of a test agent, i.e., an MTM SA derivative or
a pharmaceutically accepted salt thereof, on the activity of
target ETS transcription factor or its complex formation with
a DNA substrate and the test agent. In some embodiments,
the kit comprises a detectably labeled or unlabeled test agent
and/or a detectably labeled or unlabeled DNA substrate
and/or a detectably labeled target ETS transcription factor
such as FLil or ERG. The kit can further comprise instructions for using the kit to detect target protein or nucleic acid.
In particular, the kit comprises an engineered ETS transcription factor comprising a DNA binding domain of SEQ ID
NO:Ol or SEQ ID N0:02, wherein the transcription factor
includes at least one amino acid substitution at any of amino
acid residues corresponding to residues Tyr6S, Lys75,
His77, Gly7S, Lys79, ArgSO, TyrSl, AlaS2 of SEQ ID
NO:Ol or SEQ ID N0:02.

tryptic soy broth (TSB) and grown for 24 hr in an orbital
shaker at 2S° C., 250 rpm. After 24 hrs 4 mL of the TSB
culture was used to start a culture in R5A media in 40, 100
mL flasks. The cultures in R5Amedia were grown for 3 days
at 2S° C., 250 rpm while the production of SA was monitored by HPLC. After 3 days the cells were collected with 50
g/L of celite and removed by filtration. The cell pellet was
then re-dissolved in MeOH and sonicated for 1 hr to lyse the
cells. Following the cell lysis the cellular debris was filtered
off and the MeOH was evaporated from the filtrate. The
dried cellular extract was then reconstituted in water and
loaded onto a 5x12 em CIS RP column equilibrated with 10
column volumes of water. The column was washed with
10% ACN in water, followed by a fractionation of ACN in
water from 20-50%, followed by 100% ACN. The filtrate
removed from the cells in step one was added to the CIS
column and eluted by the same fractionation procedure. The
samples were dried and re-constituted in SO% MeOH and
water. SA was then completely isolated from the mixture of
a few compounds by semi-preparative HPLC.
Synthetic Modification of MTM SA 3 Side Chain
MTM SA was modified by converting the terminal carboxylic acid group with a primary amine through a coupling
reaction. Several different protocols were investigated to
discover the optimal reaction conditions. For all of the
exploratory reactions 2 mg ofMTM SA was used. The initial
reaction was completed by reacting MTM SA with the
desired side chain modifying molecule in a 3x molar ratio,
3xDIPEA and lxTBTU in 500 DCM starting at 4o C. The
reaction was monitored at 2 h by HPLC-MS and allowed to
proceed a total 24 h with the products analyzed by HPLCMS. For HPLC-MS analysis a small aliquot was removed
from the reaction mixture, the solvent dried off, and then
reconstituted in methanol for analysis. For the initial reaction an extract on with ethyl acetate and the separation of the
aqueous and organic phase was attempted, however this was
not repeated with the subsequent reactions. The reaction was
then repeated with 3xDIPEA, lOx of the side chain modification molecule, and 2x of the coupling agent DPPA in
DMF, starting at 4° C. and monitored at 24 and 36 h. The
protocol was modified and optimized by returning to 3x of
the desired side chain modification molecule and while
substituting the coupling agents COMU or PyBOP and the
solvent DCM or DMF in different combinations. The reactions were checked at 24 and 4S h. After the reactions were
completed the solvent was removed and the product mixture
was reconstituted in methanol. The mixture was analyzed by
HPLC-MS using a combination of the mass and UV absorbance to identifY the elution peaks corresponding to the
expected products. HPLC was then used to isolate the
individual compounds. The organic solvents were removed
from the samples followed by the freeze drying of the
compounds. To scale up the production of the compounds 10
mg of SA was reacted with 3x of the side chain molecule,
3xDIPEA, 2x PyBOP in DCM, starting at 4o C., for 24 h.
The solvent was removed and the products were reconstituted in methanol and isolated by HPLC. The side chain
modification molecules included methyl hydrazine, L-cysteine methyl ester, L-glycine methyl ester, L-alanine methyl
ester, L-valine methyl ester, cystamine, N,N-dimethylethylenediamine, and 1-amino-2-propanone (FIG. 2).
Structure Confirmation
The structures of the most active derivatives from the
reactions with MTM SA and L-glycine methyl ester, L-alanine methyl ester, and L-valine methyl ester were confirmed
through H 1 and C 13 NMR along with MALDI-TOF mass
spectrometry performed by the University of Kentucky
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EXAMPLES
The following examples are intended to further illustrate
certain preferred embodiments of the invention and are not
limiting in nature. Those skilled in the art will recognize, or
be able to ascertain, using no more than routine experimentation, numerous equivalents to the specific substances and
procedures described herein.
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Example 1
Biosynthesis of MTM SA Derivatives
Materials and Methods
N,N'-diisopropylcarbodiimide (DIC), N-hydroxysuccinimide (NHS), dimethylformamide (DMF), dichloromethane
(DCM), 0-(Benzotriazol-1-yl)-N,N,N' ,N"-tetramethyluronium tetrafluoroborate (TBTU), COMU, diphenyl phosphoryl azide (DPPA), N,N-diisopropylethylamine (DIPEA),
methyl hydrazine, benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP), L-cysteine methyl
ester hydrochloride, L-glycine methyl ester hydrochloride,
L-alanine methyl ester hydrochloride, L-valine methyl ester
hydrochloride, cystamine, DMSO (molecular biology grade,
99.9%), dimethylsulfoxide-d 6 (DMSO-d6 ), resazurin
sodium salt, were purchased from Sigma-Aldrich (USA).
N,N-dimethylethylenediamine was purchased from TCI
America (USA). 1-amino-2-propanone was purchased from
Waterstone Tech (USA). Methanol (MeOH), acetonitrile
(ACN), celite, CIS RP silica gel, tryptic soy broth (TSB),
LB broth, Difco agar, sucrose, potassium sulfate, magnesium chloride, glucose, casamino acids, yeast extract,
MOPS, and trace elements were purchased from Fisher
Scientific (USA). Streptomyces argillaceus ATCC 12956,
A549 tissue culture cells, F-12K media, fetal bovine serum
(FBS) were purchased from ATCC (USA).
Biosynthesis of MTM SA
MTM SA was produced by an adapted procedure reported
previously. S. argillaceus M7Wl was plated on R5A agar
and allowed to grow for four days or until spores formed.
The spores were then used to seed a culture in 100 mL of
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Mass Spectrometry Facility. The NMR measurements were
taken on a 500 MHz NMR in methanol-d4
In Vitro Cytotoxicity Assays
The cytotoxic effects of the side chain modifications of
SA were investigated in order to determine whether the
modification were beneficial to the drug structure. All cytotoxicity assays were performed with A549, human nonsmall cell lung cancer cells. A549 cells were cultured as
specified from ATCC at 37° C., 5% C0 2 . The cells were
added to a 96 well plate (5,000 cells/well) and permitted to
attach for 24 h. After 24 h culture media were replaced with
the side chain modified MTM SA derivative containing
media at differing concentrations. The cells were incubated
with the drug containing media for 72 hrs total (n=S). Cell
viability was determined using a resazurin assay that signifies mitochondrial metabolic activity in living cells. I 0 pL of
a I mM resazurin solution in PBS was added to the control
and analogue-treated cells at the end of the treatment period.
Cell viability was determined three hours later by reading
the fluorescence at 560 nm (Ex)/590 nm (Em). The fluorescence signals were quantified using a Spectramax M5 plate
reader (Molecular Devices) equipped with a SoftMaxPro
software. Cytotoxicity was determined by calculating the
half maximal inhibitory concentration (IC 50 ) of each
sample.
Biotechnological Production of MTM SA
MTM SA was successfully produced by the S. argillaceus
M7WI and isolated through an adapted procedure developed previously. Spores of S. argillaceus were formed by
plating the cells of the M7WI mutant strain on R5A agar and
allowing them to grow until spores were formed. Colonies
of the S. argillaceus cells began to appear after incubation
for two days and after three days spores were observed. The
cells were allowed to incubate for one more day to allow the
majority of the cells to exist as spores and then added to TSB
media. Once transferred to the TSB the cells grew quickly
and after 24 h the TSB culture was used to inoculate multiple
flasks of R5A media to produce SA. The pH of the R5A
media was adjusted to pH 6.S5. HPLC was used to monitor
the culture for the production of SA. After 72 h the culture
production was primarily composed of the end products
including MTM SK and MTM SDK in addition to MTM
SA, and the culture was terminated. A large portion of the
MTM SA production is excreted into the culture media so
once the culture process was stopped the media and the cells
were separated. Celite cell binding resin was used to bind the
cells and allow the culture to more easily be separated
through filtration. CIS RP silica gel was able to successfully
collect MTM SA from the complex culture mixture. Other
compounds were also collected by the column so initial
washes of I 0% and 20% ACN were used to remove many of
the byproducts from the sample. Further fractionation of the
culture on the CIS RP column in addition to the loading and
subsequent fractionation on a new, smaller CIS RP column
did not aid in the isolation of MTM SA from the other MTM
analogues so all compounds were eluted to together with
I 00% ACN to minimize dilution. There was also still some
MTM SA contained inside the cells removed in the initial
filtration step so the cells were lysed by sonication in
methanol to release the intracellular content including all the
MTM SA. Filtration removed the cellular debris, followed
by the removal of the methanol. The same procedure as with
the culture media then resulted in a relatively simple mixture
of MTM SA along with the other MTM analogues and a few
other impurities. Since the fractionation of the sample on the
CIS RP silica gel did not completely isolate MTM SA from
the other analogues the final purification steps were per-

formed by using semi-preparative HPLC. The individual
peak corresponding to MTM SA was collected and analyzed
for purity using HPLC-MS. MTM SA was able to be
collected at >95% purity and was stored at 20° C. until
further use.
Synthetic Modification of MTM SA 3 Side Chain (I)
Once produced, MTM SA was modified chemically by
taking advantage of the terminal carboxylic acid on the
3-side chain of the molecule. Several different protocols
were attempted in order to discern the most favorable
reaction conditions. The reactions were monitored by HPLC
and the ratio of the signal corresponding to MTM SA was
compared to the appearance of any new peaks following the
reaction. MTM SA eluted with a retention time of 16.5 min,
showing absorption of 410 nm and a mass to charge ratio of
m/z 1026. The initial reaction with methyl hydrazine and
TBTU as a coupling agent in DCM only displayed SA as the
major component of the mixture after 2 h with only very
minor other peaks appearing. After 24 h the MTM SA peak
was gone with several broad peaks with shorter retention
times appeared. The initial attempt to separate the products
by ethyl acetate extraction did not result in favorable results
and thus was not repeated. The reaction was then repeated
with methyl hydrazide with the DPPA coupling agent in
DMF. The reaction was also performed with 1-amino-2propanone under the same conditions. After 24 h a new peak
at 14.0 min appeared equal in intensity to that of the MTM
SA peak. The expected product had a m/z of 1054.4, the
same as the 14.0 min peak of 1054.4. The absorption of the
peak was shifted however to 440 nm. The reaction with the
1-amino-2-propanone did not produce a new peak even after
36 hrs. The reaction was then repeated using the coupling
agent COMU in DMF with the side chains L-glycine methyl
ester hydrochloride and N,N-dimethylethylenediamine. For
the reaction with N,N-dimethylethylenediamine a new product appeared with a retention time of 11.25 min, a UV-Vis
absorption of 410 nm and a m/z matching that of the
expected product of 1096.6 (1096.5 expected). For the
reaction with L-glycine methyl ester hydrochloride three
new products were formed with retention times of 14.4,
15.6, and 17.0 min. The UV-Vis absorption for the peaks
were 455 nm, 455 nm, and 410 nm with 1097.3, 116S.4, and
1097.3 m/z, respectively. The calculated m/z for the correct
product of the reaction with L-glycine methyl ester hydrochloride is 1097.4 m/z. There was still also a small peak
corresponding to MTM SA. The reaction of MTM SA with
cystamine was performed in DMF with COMU and resulted
in the formation of a new peak at 9.0 min with absorption of
455 nm and m/z 1160.6. The theoretical m/z of the expected
product was IOS5.S but if a disulfide bond were to form
between an attached side chain molecule and a free side
chain molecule the expected m/z would be 1160.4 m/z. The
reaction solvent was then switched to DCM and L-alanine
methyl ester hydrochloride was used as the side chain
modification molecule. This reaction resulted in the formation of one new peak with a retention time of IS min at
roughly equal intensity to that of the MTM SA peak and a
UV-Vis of 410 nm and a m/z of 1111.3. The calculated m/z
of the expected molecule was 1111.4. The same conditions
were used with L-valine methyl ester hydrochloride as well
which resulted in a new molecule with a retention time of
20.6 min, a UV-Vis absorption of 410 nm and a m/z of
113 9. 5. The peak was the major product compared to the SA
peak. The calculated m/z of the expected product was
1139.5. The reactions with L-glycine methyl ester hydrochloride and N,N-dimethylethylenediamine were then
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repeated with DCM as the solvent and PyBOP as the
coupling agent. These reactions resulted in the formation of
one new product with a retention time of 11.0 min for the
N,N-dimethylethylenediamine reaction and 17.0 min for the
L-glycine methyl ester hydrochloride reaction. Both products at a UV-Vis absorption of 410 nm and the m/z of the
expected products identified previously. The individual
peaks were collected from HPLC, the ACN removed, and
freeze dried for use with the in vitro cytotoxicity assays.
Exemplary routes for synthesizing MTM SA and its use
for 3-side chain derivatization are depicted in FIG. 2.
Briefly, the mtmW deletion mutant of Streptomyces argillaceus M7W1 will be used, which produces -50% MTM SA
along with each 25% of MTMs SK and SDK. The unique
carboxyl moiety ofMTM SA allows a simple derivation into
amides or esters. Initially short amide side chains will be
generated using PyBop (benzotriazol-1-yl-oxytri -pyrrolidina-phosphonium hexafluoro-phosphate) or similar selective coupling reagents. The approach allows introducing
N-atoms and other hydrogen bond donor and/or acceptor
atoms into the side chain, thereby modifying its proteinbinding properties. As an alternative to isolating MTM SA
from the M7W1 mutant, the inventors also designed an
enzymatic strategy using the premithramycin B (5) producing mtmOIV deletion mutantS. argillaceus M704 (production -100 mg/L 5). FIG. 2 shows some examples of amino
acid derivatives, including a set ofMTM SA Trp derivatives
some of which may be isotope-labeled variants to be used to

side chain modified molecules including MTM SA-Ala,
-Ser, -Cys, -His, -Trp, -Tyr, -Phe, -PheGly, -Phe-Allylox are
shown in FIG. 2.
Structure Confirmation by NMR
The structures ofMTM SA-L-glycine methyl ester hydrochloride, MTM SA-L-alanine methyl ester hydrochloride,
and MTM SA-L-valine methyl ester hydrochloride were
confirmed by H 1 and C 13 NMR. The mass of the derivatives
was also confirmed by mass spectrometry. For MTM SA-Lglycine methyl ester hydrochloride the expected mass+Na
was 1120.45 and the observed mass was 1120.45, for MTM
SA-L-alanine methyl ester hydrochloride the expected product had a calculated mass+Na of 1134.47 and the observed
mass was 1134.47, and for MTM SA-L-valine methyl ester
hydrochloride 1162.50 and observed mass was also 1162.50.
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In Vitro Cell Toxicity Assays
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The cytotoxicity of a subgroup of the MTM SA analogues
was tested against various Ewing sarcoma cell lines and
non-Ewing sarcoma cell lines over a 72 hour period. Each
analogue was checked individually with a range of concentrations to determine the IC 50 of the molecule in actively
growing cell cultures. For comparison, the cytotoxicity of
MTM and MTM SK, an analogue discovered previously and
found to be more active than the regular MTM were also
investigated. The IC 50 values are shown in Table 2 below.

TABLE 2
IC 50 values of MTM Analogs in Various Ewing Sarcoma and Non-Ewing Sarcoma Cell lines
NON-EWING SARCOMA CELL LINES

EWING SARCOMA CELL LINES
IC50
(nM)
MTM
MTMSK
MTMS
A-Trp
MTMS
A-Phe
MTMS
ATryptamine
MTMS
A-5-BrTrp
MTMS
A-Me
ester
MTMS
A-50Me
Tryparnine
MTMS
A-Tyr
MTMS
ASerotonin
MTMLys2PGs

TC
32
28
23
18

5838

SKES-1

A673

43
23
10

26
25
38

36
37
44

RH ES
TC71 RDES 30 -2

25
31
34

109

36
40
39
94

47
62
48

42
39
63

ES
-3

ES ES ES
-4 -7 -8 A549 U118

51
56
64

22
32
33

32
42
41

37
44
40

63
30
87

136 182 363

35

61

59

398

48
56

110

439

226

78

155 216

90

86

97

196

76

29

15

219

68

159 210 102

76

50

316

59

67

193

86

46

76

90

41

51

47

99

38

73

78

63

58

84 157

63

79

75

84

58

133

170

306

130

263 266 138 189 171

867

231

667

690

612

671

749 658 610 753 676 >3000

916

DU
145

C42

VCaP

HCT116

OVCAR-

PC3
57
37
45

31
32
31

81
89
96

33
36
20

29
31
23

26
29
72

32

21
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mark hot-spots of interaction. As shown in FIG. 2, MTM SA
can be isolated either from mutant M7W1 (20 mg/L) or
enzymatically converted from premithramycin B, which is
produced at 100 mg/L from the M704 mutant. Exemplary
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methods was used to modifY the relatively inactive MTM
SA that is accumulated alongside the biologically improved
MTM analogues MTM SK and MTM SDK. The latter two
molecules, which are both considerably more active and
significantly less toxic than the natural product MTM itself,
pointed in the direction that 3-side chain modifications can
be advantageous. The modification of the 3-side chain of
MTM SA with amino acid derivatives yielded several active
compounds with the MTM SA-Trp and MTM SA-Phe,
which exhibit high cytotoxicity against Ewing sarcoma cells
and cancer cell specificity.

analogues display higher affinity for A-form DNA (e.g.
Kd=2.7 f.LM for GGGATCCC (SEQ ID N0:04)), than for
B-form DNA (e.g. Kd>15 f.LM for GGAATTCC (SEQ ID
N0:05).
EWS-FLI1 and several constructs of FLil DNA binding
domain (DBD) were expressed in E. coli and purified to
homogeneity by a combination of N?+-chelating and size
exclusion chromatography. EWS-FLI1 required refolding,
as described previously (Uren eta!. (2004) Biochemistry 43,
13579-89), whereas FLI1 DBD were expressed as soluble
proteins free from aggregation (not shown). AnN-terminal
deca-His tag (SEQ ID NO: 11) was cleaved by Prescission
protease. These proteins displayed robust binding to consensus DNA containing the central GGAA (SEQ ID N0:06)
recognition sequence and to a GGAA (SEQ ID N0:06)
repeat sequence that is critical for EWS-FLil binding and
oncogenesis in vivo (not shown).

5

10

Example 3
Interaction Between MTM and the DNA Binding
Domain of EWS-FLI1
A complex ofMTM SA-Trp (a potent and highly selective
analogue) with a strong binding double-stranded DNA oligomer (with the core sequence GGCC (SEQ ID N0:03))
was crystallized and the crystal structure of the complex was
determined at 2.0 A resolution. This crystal structure of the
MTM-DNA complex provided a view of DNA recognition
by MTM in atomic detail. The crystal structure of the
complex showed that MTM SA-Trp is bound to DNA as a
dimer, whose monomers are coordinated together by a
divalent metal ion, consistent with previous NMR-molecular
dynamics studies. Only five hydrogen bonds per MTM
monomer are observed between MTM SA-Trp and DNA
bases (direct and water-mediated), and they constitute a very
minor fraction of the intermolecular contacts and do not
appear to be sequence-specific. Indeed, MTM SA binds a
variety of DNA sequences, as previously shown (Hampshire
et a!. (2008) Biochimie 90, 988-98). The majority of intermolecular contacts are made between the drug and the DNA
backbone as MTM SA-Trp is bound to the minor groove of
the DNA. Therefore, the DNA backbone conformation is
likely a determining factor in MTM-DNA binding. Notably,
the DNA in this structure is A-form, rather than B-form,
providing a wide minor groove and a distinct relative
base-pair disposition. To determine whether this DNA conformation is induced by MTM, the DNA was crystallized
alone and its structure was determined at 1.65 A resolution.
The unbound DNA, similar to bound DNA, is A-form,
suggesting that it is the A-form of the DNA and not the
sequence alone (MTM is thought to bind GC-rich DNA) that
is a determinant of MTM-DNA binding. Notably, the solvent-exposed 3-side chain of MTM SA-Trp bearing the Trp
residue protrudes away from the DNA; it is positioned
appropriately for interacting with DNA-binding factors.
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Example 4
Binding of MTM/Analogues and EWS-FLI1/FLI1
DBD to DNA
MTM and its analogues are intrinsically fluorescent and
their fluorescence decreases upon divalent metal-dependent
dimerization. This property was used to establish (by titration of MgC1 2 into MTM/analogues) that at physiological
salt concentration (5 mM MgC12, 100 mM NaCI), MTM
analogues are dimeric (not shown). The fluorescence of
dimeric MTM is strongly (6-fold) enhanced upon DNA
binding. By monitoring this fluorescence enhancement, the
ability of MTM/analogues to bind several known A-form
and B-form DNA oligomers was tested. In agreement with
the crystal structure data, it was shown that MTM and its

The FLil DBD, which is the DNA interacting part of
EWS-FLI1, is highly conserved in the ETS family of transcription factors, which include ERG, another protein found
as a fusion with EWS in Ewing sarcomas. A recently
reported crystal structure of ERG DBD in complex with the
consensus DNA containing GGAA (SEQ ID N0:06) core
(Regan eta!. (2013) Proceedings of the National Academy
of Sciences of the United States of America 110, 133 74-9),
shows that ERG DBD is bound in the major groove of the
GGAA (SEQ ID N0:06) region, with the minor groove
immediately upstream widened and A-form like. Because
MTM binds to the minor groove of A-form DNA and ERG
DBD, like FLI1 DBD, binds in the nearby major groove,
binding ofMTM and EWS-FLil to DNA is not competitive,
but cooperative. Indeed, the model of MTM SA Trp positioned in (and stabilizing) the widened groove of the ERG
DBD-DNA complex as observed in the crystal structure
shows that the drug and the protein do not clash. The
structural and biochemical data indicate that MTM and
EWS-FLI1 bind to distinct neighboring structural regions of
DNA via cooperative binding. Furthermore, the Trp side
chain ofMTM SA Trp and the terminal sugar moiety ofthe
disaccharide tail of MTM interact with ERG DBD. This
cooperative binding is responsible for the observed 1) highly
potent (low-nM) antagonism ofEWS-FLI1 by MTM and its
analogues (FIG. 9), despite much weaker affinity (low-f.LM,
at best) ofMTM for DNA in the absence of other factors and
2) modulation of potency and anti-Ewing sarcoma selectivity in cell culture assays by modifications of the 3-side chain
ofMTM.
Example 6
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Crystallization, Data Collection and Crystal
Structure Determination of MTM SA Trp-DNA
Complex
60

65

1 f.LL drops containing a mixture of 2 mM MTM SA Trp
(diluted from a 20 mM DMSO stock) and 2 mM of 10-mer
palindromic DNA (forms 1 mM of double-stranded DNA
oligonucleotide by self-annealing in 10 mM sodium cacodylate, pH 6.5) having the sequence: 5'-AGAGGCCTCT-3'
(SEQ ID N0:9) in 10 mM ZnC1 2 and 1 mM spermidine,
were set up as hanging drops over 1 mL of the reservoir
solutions of varying concentrations of MPD in the range
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10-20% MPD. The crystals appeared within a week. The
crystals were rapidly frozen in liquid nitrogen directly from
the drop. The X-ray diffraction data were collected at the
Advanced Photon Source, at Argonne National Laboratory.
The crystal structure was determined by the single anomalous dispersion (SAD) method, by using the anomalous
signal from Zn2 +. The crystal structure of MTM SA TrpDNA complex was refined to the resolution of 2 A. The
crystals contain two complexes of mithramycin dimer with
double-stranded DNA in the asymmetric unit.

and MTM SA-Trp yielded 9-fold selectivity against Ewing
sarcoma cells relative to non-Ewing cells (FIG. 9, right
panel). MTM SA-Phe was surprisingly found to be even
more potent and highly selective in killing of Ewing sarcoma cells than other MTM SA derivatives. As shown in
FIG. 10, MTM SA-Phe showed significantly improved
selectivity in the context of a target ETS transcription factor
containing a DNA binding domain of SEQ ID NO:Ol or
SEQ ID N0:02.

5

10

Example 7
Modeling the Structure of the Ternary Complex of
MTM SA Trp-DNA-ERG DNA Binding Domain
An approximate model of a ternary complex of MTM
SA-DNA-ERG DBD was constructed. The ERG DBD is
nearly identical (with 98% sequence identity) to FLil DBD
and MTM SA analogues are similarly active against EWSERG and EWS-FLI1 tumor cells. The atomic coordinates for
all components of the model are given below. The side chain
of the MTM SA molecule directly interacts with ERG.
Specifically, the MTM interacting residues in ERG are:
Tyr356, Lys363, His365, Gly366, Lys367, Arg368, Tyr369,
Ala370.
FLI1 (SEQ ID NO: 07, FIG. 6) and ERG (SEQ ID N0:08,
FIG. 7) contain nearly identical DNA binding domains and,
therefore, all observations in this study that apply to the
ERG DNA binding domain, apply to the FLI1 DNA binding
domain. Accordingly, the MTM interacting residues ofFLI1
are: Tyr343, Lys350, His352, Gly353, Lys354, Arg355,
Tyr356, Ala357 of SEQ ID N0:07. For both ERG and FLil,
the MTM interacting residues are within the DNA binding
domains of these proteins and correspond to residues Tyr68,
Lys75, His77, Gly78, Lys79, Arg80, Tyr81, Ala82 of SEQ
ID N0:01 & SEQ ID N0:02, provided in FIG. 8.

The Effect of MTM and its Analogues on
EWS-FLI1-Mediated Transcription
15
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Selectivity Assays-Ewing Sarcoma Cells Versus
Non-Ewing Sarcoma Cells
MTM analogues MTM SA-Ala and MTM SA-Trp display
higher selectivity than MTM against Ewing sarcoma cells
relative to non-Ewing cells (FIG. 9). Cytotoxicity of MTM
and its analogues against a panel of actively growing Ewing
sarcoma (TC32, 5838, SKES1) and non-Ewing (A459 (lung)
and PC3 (prostate)) cancer cell lines were measured (72 hr).
MTM displayed an IC 50 =15 nM against the Ewing sarcoma
panel. Remarkably, it was subsequently found that two
MTM analogues, MTM SA-Ala and MTM SA-Trp show
3-fold higher selectivity than does MTM against Ewing
sarcoma relative to non-Ewing cell lines (FIG. 9), with
MTM SA-Ala being about 200-fold less potent than MTM,
while MTM SA-Trp is about 3-fold more potent as well as
3-fold more selective than MTM against Ewing sarcoma
cells. The modifications of the 3-side chain in MTM SA-Ala
SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS, 11
<210> SEQ ID NO 1
<211> LENGTH, 98
<212> TYPE, PRT
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Studies were conducted using MTM and lead analogs
(mithramycin-SK (MTM-SK), mithramycin-SA-tryptophan
and
mithramycin-SA-phenylalanine
(MTM-SA-Trp ),
(MTM-SA-Phe)). EWS-FLil promoter occupancy was
investigated using chromatin immune precipitation real time
PCR (ChiP-RTPCR). The effect of drug treatment on
expression of genes controlled by EWSFLI1 was evaluated
by quantitative real-time PCR (qRT-PCR) (FIG. 11). The
effect of treatment with 100 nM of drug for 24 hours on cell
cycle distribution was also compared among analogs (FIG.
12(b)). In vitro efficacy was evaluated by estimating GI 50
parameters (72-hr) (FIG. 12(a)). In addition, the maximum
tolerated dose (MTD) and the effect of treatment on plasma
total-calcium were used to assess relative toxicity in mice.
EWS-FLI1 promoter occupancy upstream from Nr0b1,
Tgfbr2, and Rcorl genes was evaluated in Ewing sarcoma
cells (TC32 cells) by ChiP-RTPCR. MTM and MTM-SATrp analog destabilized FLil binding to all three promoters
and MTM-SA-Trp was shown to be the most destabilizing.
Comparatively, MTM-SK appears to mostly stabilize FLil.
Additionally, qRTPCR showed that MTM and its analogs
efficiently down-regulated mRNA expression in a dose
dependent manner (rank-order of efficiency: MTM-SATrp>MTM=MTM-SK). (FIG. 11). These data were in
accord with the in vitro cytotoxicity data that show MTMSA-Trp has relatively higher potency (lower GI 50 ) among
Ewing cell lines (n=8) as compared to other analogs. (FIG.
12(a)). Furthermore, the effect of drug treatment appears to
lead to differences in cell-cycle progression. MTM and
MTM-SK treated TC32 cells were primarily in G1/G2
phase, whereas MTM-SA-Trp treated cells showed
increased S-phase accumulation. (FIG. 12(b)).
Only the preferred embodiment of the present invention
and examples of its versatility are shown and described in
the present disclosure. It is to be understood that the present
invention is capable of use in various other combinations
and environments and is capable of changes or modifications
within the scope of the inventive concept as expressed
herein. Thus, for example, those skilled in the art will
recognize, or be able to ascertain, using no more than routine
experimentation, numerous equivalents to the specific substances, procedures and arrangements described herein.
Such equivalents are considered to be within the scope of
this invention, and are covered by the following claims.
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-continued
<213> ORGANISM, Artificial Sequence
<220> FEATURE,
<223> OTHER INFORMATION, Description of Artificial Sequence, Synthetic
polypeptide
<400> SEQUENCE, 1
Pro Gly Ser Gly Gln Ile Gln Leu Trp Gln Phe Leu Leu Glu Leu Leu
1
5
10
15
Ser Asp Ser Ala Asn Ala Ser Cys Ile Thr Trp Glu Gly Thr Asn Gly
20
25
30
Glu Phe Lys Met Thr Asp Pro Asp Glu Val Ala Arg Arg Trp Gly Glu
35
40
45
Arg Lys Ser Lys Pro Asn Met Asn Tyr Asp Lys Leu Ser Arg Ala Leu
50
55
60
Arg Tyr Tyr Tyr Asp Lys Asn Ile Met Thr Lys Val His Gly Lys Arg
65
70
75
80
Tyr Ala Tyr Lys Phe Asp Phe His Gly Ile Ala Gln Ala Leu Gln Pro
85
90
95
His Pro

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 2
LENGTH, 98
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
polypeptide

<400> SEQUENCE, 2
Pro Gly Ser Gly Gln Ile Gln Leu Trp Gln Phe Leu Leu Glu Leu Leu
1
5
10
15
Ser Asp Ser Ser Asn Ser Ser Cys Ile Thr Trp Glu Gly Thr Asn Gly
20
25
30
Glu Phe Lys Met Thr Asp Pro Asp Glu Val Ala Arg Arg Trp Gly Glu
35
40
45
Arg Lys Ser Lys Pro Asn Met Asn Tyr Asp Lys Leu Ser Arg Ala Leu
50
55
60
Arg Tyr Tyr Tyr Asp Lys Asn Ile Met Thr Lys Val His Gly Lys Arg
65
70
75
80
Tyr Ala Tyr Lys Phe Asp Phe His Gly Ile Ala Gln Ala Leu Gln Pro
85
90
95
His Pro

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 3
LENGTH, 4
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 3
ggcc

<210>
<211>
<212>
<213>
<220>
<223>

4

SEQ ID NO 4
LENGTH, 8
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

US 9,447,135 B2
38

37
-continued
<400> SEQUENCE, 4
gggatccc

<210>
<211>
<212>
<213>
<220>
<223>

8

SEQ ID NO 5
LENGTH, 8
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 5
ggaattcc

<210>
<211>
<212>
<213>
<220>
<223>

8

SEQ ID NO
LENGTH, 4
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE,
ggaa

<210>
<211>
<212>
<213>
<220>
<223>

4

SEQ ID NO 7
LENGTH, 452
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
polypeptide

<400> SEQUENCE, 7
Met Asp Gly Thr Ile Lys Glu Ala Leu Ser Val Val Ser Asp Asp Gln
1
5
10
15
Ser Leu Phe Asp Ser Ala Tyr Gly Ala Ala Ala His Leu Pro Lys Ala
20
25
30
Asp Met Thr Ala Ser Gly Ser Pro Asp Tyr Gly Gln Pro His Lys Ile
35
40
45
Asn Pro Leu Pro Pro Gln Gln Glu Trp Ile Asn Gln Pro Val Tyr Val
50
55
60
Asn Val Lys Arg Glu Tyr Asp His Met Asn Gly Ser Arg Glu Ser Pro
65
70
75
80
Val Asp Cys Ser Val Ser Lys Cys Ser Lys Leu Val Gly Gly Gly Glu
85
90
95
Ser Asn Pro Met Asn Tyr Asn Ser Tyr Met Asp Glu Lys Asn Gly Pro

100

105

110

Pro Pro Pro Asn Met Thr Thr Asn Glu Arg Arg Val Ile Val Pro Ala

115

120

125

Asp Pro Thr Leu Trp Thr Gln Glu His Val Arg Gln Trp Leu Glu Trp
130
135
140
Ala Ile Lys Glu Tyr Ser Leu Met Glu Ile Asp Thr Ser Phe Phe Gln
145
150
155
160
Asn Met Asp Gly Lys Glu Leu Cys Lys Met Asn Lys Glu Asp Phe Leu
165
170
175
Arg Ala Thr Thr Leu Tyr Asn Thr Glu Val Leu Leu Ser His Leu Ser
180
185
190
Tyr Leu Arg Glu Ser Ser Leu Leu Ala Tyr Asn Thr Thr Ser His Thr
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195

200

205

Asp Gln Ser Ser Arg Leu Ser Val Lys Glu Asp Pro Ser Tyr Asp Ser
210
215
220
Val Arg Arg Gly Ala Trp Gly Asn Asn Met Asn Ser Gly Leu Asn Lys
225
230
235
240
Ser Pro Pro Leu Gly Gly Ala Gln Thr Ile Ser Lys Asn Thr Glu Gln
245
250
255
Arg Pro Gln Pro Asp Pro Tyr Gln Ile Leu Gly Pro Thr Ser Ser Arg
260
265
270
Leu Ala Asn Pro Gly Ser Gly Gln Ile Gln Leu Trp Gln Phe Leu Leu
275
280
285
Glu Leu Leu Ser Asp Ser Ala Asn Ala Ser Cys Ile Thr Trp Glu Gly
290
295
300
Thr Asn Gly Glu Phe Lys Met Thr Asp Pro Asp Glu Val Ala Arg Arg
305
310
315
320
Trp Gly Glu Arg Lys Ser Lys Pro Asn Met Asn Tyr Asp Lys Leu Ser
325
330
335
Arg Ala Leu Arg Tyr Tyr Tyr Asp Lys Asn Ile Met Thr Lys Val His
340
345
350
Gly Lys Arg Tyr Ala Tyr Lys Phe Asp Phe His Gly Ile Ala Gln Ala
355
360
365
Leu Gln Pro His Pro Thr Glu Ser Ser Met Tyr Lys Tyr Pro Ser Asp
370
375
380
Ile Ser Tyr Met Pro Ser Tyr His Ala His Gln Gln Lys Val Asn Phe
385
390
395
400
Val Pro Pro His Pro Ser Ser Met Pro Val Thr Ser Ser Ser Phe Phe
405
410
415

Gly Ala Ala Ser Gln Tyr Trp Thr Ser Pro Thr Gly Gly Ile Tyr Pro
420
425
430
Asn Pro Asn Val Pro Arg His Pro Asn Thr His Val Pro Ser His Leu
435
440
445

Gly Ser Tyr Tyr
450

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 8
LENGTH, 462
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
polypeptide

<400> SEQUENCE, 8
Met Ile Gln Thr Val Pro Asp Pro Ala Ala His Ile Lys Glu Ala Leu
1
5
10
15
Ser Val Val Ser Glu Asp Gln Ser Leu Phe Glu Cys Ala Tyr Gly Thr
20
25
30
Pro His Leu Ala Lys Thr Glu Met Thr Ala Ser Ser Ser Ser Asp Tyr
35
40
45
Gly Gln Thr Ser Lys Met Ser Pro Arg Val Pro Gln Gln Asp Trp Leu
50
55
60
Ser Gln Pro Pro Ala Arg Val Thr Ile Lys Met Glu Cys Asn Pro Ser
65
70
75
80
Gln Val Asn Gly Ser Arg Asn Ser Pro Asp Glu Cys Ser Val Ala Lys
85
90
95
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42
-continued

Gly Gly Lys Met Val Gly Ser Pro Asp Thr Val Gly Met Asn Tyr Gly
100
105
110
Ser Tyr Met Glu Glu Lys His Met Pro Pro Pro Asn Met Thr Thr Asn
115
120
125
Glu Arg Arg Val Ile Val Pro Ala Asp Pro Thr Leu Trp Ser Thr Asp
130
135
140
His Val Arg Gln Trp Leu Glu Trp Ala Val Lys Glu Tyr Gly Leu Pro
145
150
155
160
Asp Val Asn Ile Leu Leu Phe Gly Asn Ile Asp Gly Lys Glu Leu Cys
165
170
175
Lys Met Thr Lys Asp Asp Phe Gln Arg Leu Thr Pro Ser Tyr Asn Ala
180
185
190
Asp Ile Leu Leu Ser His Leu His Tyr Leu Arg Glu Thr Pro Leu Pro
195
200
205
His Leu Thr Ser Asp Asp Val Asp Lys Ala Leu Gln Asn Ser Pro Arg
210
215
220
Leu Met His Ala Arg Asn Thr Asp Leu Pro Tyr Glu Pro Pro Arg Arg
225
230
235
240
Ser Ala Trp Thr Gly His Gly His Pro Thr Pro Gln Ser Lys Ala Ala
245
250
255
Gln Pro Ser Pro Ser Thr Val Pro Lys Thr Glu Asp Gln Arg Pro Gln
260
265
270
Leu Asp Pro Tyr Gln Ile Leu Gly Pro Thr Ser Ser Arg Leu Ala Asn
275
280
285
Pro Gly Ser Gly Gln Ile Gln Leu Trp Gln Phe Leu Leu Glu Leu Leu
290
295
300
Ser Asp Ser Ser Asn Ser Ser Cys Ile Thr Trp Glu Gly Thr Asn Gly
305
310
315
320
Glu Phe Lys Met Thr Asp Pro Asp Glu Val Ala Arg Arg Trp Gly Glu
325
330
335
Arg Lys Ser Lys Pro Asn Met Asn Tyr Asp Lys Leu Ser Arg Ala Leu
340
345
350
Arg Tyr Tyr Tyr Asp Lys Asn Ile Met Thr Lys Val His Gly Lys Arg
355
360
365
Tyr Ala Tyr Lys Phe Asp Phe His Gly Ile Ala Gln Ala Leu Gln Pro
370
375
380
His Pro Pro Glu Ser Ser Leu Tyr Lys Tyr Pro Ser Asp Leu Pro Tyr
385
390
395
400
Met Gly Ser Tyr His Ala His Pro Gln Lys Met Asn Phe Val Ala Pro
405
410
415
His Pro Pro Ala Leu Pro Val Thr Ser Ser Ser Phe Phe Ala Ala Pro
420
425
430
Asn Pro Tyr Trp Asn Ser Pro Thr Gly Gly Ile Tyr Pro Asn Thr Arg
435
440
445
Leu Pro Thr Ser His Met Pro Ser His Leu Gly Thr Tyr Tyr
450
455
460

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 9
LENGTH, 10
TYPE, DNA
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
oligonucleotide

<400> SEQUENCE, 9
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agaggcctct

<210>
<211>
<212>
<213>
<220>
<223>

10

SEQ ID NO 10
LENGTH,
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
6xHis tag

<400> SEQUENCE, 10
His His His His His His
5

1

<210>
<211>
<212>
<213>
<220>
<223>

SEQ ID NO 11
LENGTH, 10
TYPE, PRT
ORGANISM, Artificial Sequence
FEATURE,
OTHER INFORMATION, Description of Artificial Sequence, Synthetic
10xHis tag

<400> SEQUENCE, 11
His His His His His His His His His His
1
5
10

What is claimed is:
1. An MTM SA derivative having the following formula:

30

35

or a pharmaceutically acceptable salt thereof; wherein Z
represents 0, S, N-R'; R and R' represent, for each
occurrence, H, alkyl, heterocyclic, aryl, heteroaryl,
provided that R is not H when Z is 0; ZR taken together
represents an organic residue; and wherein MTM 1
represents the fused ring portion of the mithramycin
structure and can include different sugars or sugar
chains.
2. The MTM SA derivative according to claim 1 having
the following formula:

40

45

50

C)yH30 /RI
N,.,

MTM1

R2
55

0

wherein R 1 and R2 can be the same or different and each
of R 1 and R 2 can be an H, an amino acid conjugate or
an ester derivative thereof, a lower straight chain or
branched alkyl unsubstituted or substituted with one or
more amino, alkyl amino, alkylcarboxyl, alkoxyl, alkylcarbonyl, hydroxyl, thio, alkyldisulfide, halo, provided
that R 1 and R 2 are not both H simultaneously.
3. The MTM SA derivative of claim 2, wherein NR 1 R 2
form a phenylalanine (Phe) conjugate or an ester derivative
thereof.

60

65

4. The MTM SA derivative of claim 2, wherein NR 1 R 2
form a tryptophan (Trp) conjugate or an ester derivative
thereof.
5. The MTM SA derivative of claim 3 wherein the
phenylalanine is substituted with an indole alkyl group.
6. The MTM SA derivative of claim 4 wherein the
tryptophan is substituted with a phenyl alkyl group.
7. A method of preparing the MTM SA derivative of claim
2, the method comprising coupling the terminal carboxylic
acid group of MTM SA with an amine.
8. A method of treating cancer or neuro-disease in a
patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of the
MTM SA derivative or a pharmaceutically acceptable salt
thereof of claim 1.
9. The method of claim 8, wherein the method comprises
treating Ewing sarcoma.
10. The method of claim 8, wherein the method comprises
treating lung cancer.
11. The method of claim 8, wherein the method comprises
treating colon cancer.
12. The method of claim 9 wherein the MTM SA derivative is a substituted or unsubstituted MTM SA-Trp or an
ester derivative thereof or a pharmaceutically acceptable salt
thereof.
13. The method of claim 9 wherein the MTM SA derivative is a substituted or unsubstituted MTM SA-Phe or an
ester derivative thereof or a pharmaceutically acceptable salt
thereof.
14. A method for selectively modulating the activity of a
target ETS transcription factor in a patient in need thereof,
including administering to the patient a therapeutically
effective amount of an MTM SA derivative or a pharmaceutically acceptable salt thereof of claim 2.
15. The method of claim 14, wherein the MTM SA
derivative is a substituted or unsubstituted MTM SA-Phe or
an ester derivative thereof or a pharmaceutically acceptable
salt thereof.
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16. The method of claim 14, wherein the MTM SA
derivative is a substituted or unsubstituted MTM SA-Trp or
an ester derivative thereof or a pharmaceutically acceptable
salt thereof.

* * * * *
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